1. Shea BJ, Hamel C, Wells GA et al: AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009; 62: 1013.
2. Cochrane handbook for systematic reviews of interventions. Chichester, West Sussex; Hoboken, NJ: John Wiley & Sons 2008.
3. Faraday M, Hubbard H, Kosiak B et al: Staying at the cutting edge: a review and analysis of evidence reporting and grading; the recommendations of the American Urological Association. BJU Int 2009; 104: 294.
4. Hsu C and Sandford B: The Delphi technique: making sense of consensus. Practical Assessment, Research & Evaluation 2007; 12: 1.
5. Impotence. NIH Consensus Statement 1992; 10: 1.
6. McCabe MP, Sharlip ID, Atalla E et al: Definitions of sexual dysfunctions in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med 2016; 13: 135.
7. Saigal CS, Wessells H, Pace J et al: Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006; 166: 207.
8. Bacon CG, Mittleman MA, Kawachi I et al: A prospective study of risk factors for erectile dysfunction. J Urol 2006; 176: 217.
9. Elwyn G, Frosch D, Thomson R et al: Shared decision making: a model for clinical practice. J Gen Intern Med 2012; 27: 1361.
10. Epstein RM, Alper BS and Quill TE: Communicating evidence for participatory decision making. JAMA 2004;291: 2359.
11. Hoffmann TC and Del Mar C: Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review. JAMA Intern Med 2015; 175: 274.
12. Hatzichristou D, Rosen RC, Derogatis LR et al: Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010; 7: 337.
13. Vemulakonda VM, Sorensen MD and Joyner BD: The current state of diversity and multicultural training in urology residency programs. J Urol 2008; 180: 668.
14. McKinlay JB: The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12 Suppl 4: S6.
15. Ayta IA, McKinlay JB and Krane RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50.
16. Jackson G, Boon N, Eardley I et al: Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract 2010; 64: 848.
17. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I et al: Prevalence and independent risk factors for erectile dysfunction in Spain: results of the epidemiologia de la disfuncion erectil masculina study. J Urol 2001; 166: 569.
18. Corona G, Lee DM, Forti G et al: Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med 2010; 7: 1362.
19. Feldman HA, Goldstein I, Hatzichristou DG et al: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54.
20. Grover SA, Lowensteyn I, Kaouache M et al: The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med 2006; 166: 213.
21. Sasayama S, Ishii N, Ishikura F et al: Men's health study: epidemiology of erectile dysfunction and cardiovascular disease. Circ J 2003; 67: 656.
22. Kloner RA: Erectile dysfunction in the cardiac patient. Curr Urol Rep 2003; 4: 466.
23. Montorsi P, Ravagnani PM, Galli S et al: The triad of endothelial dysfunction, cardiovascular disease, and erectile dysfunction: clinical implications. European Urology, Supplements 2009; 8: 58.
24. El-Sakka AI: Association of risk factors and medical comorbidities with male sexual dysfunctions. J Sex Med 2007; 4: 1691.
25. Hodges LD, Kirby M, Solanki J et al: The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract 2007; 61: 2019.
26. Montorsi F, Briganti A, Salonia A et al: Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360.
27. Inman BA, Sauver JL, Jacobson DJ et al: A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009; 84: 108.
28. Fung MM, Bettencourt R and Barrett-Connor E: Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 2004; 43: 1405.
29. Esposito K, Giugliano F, Martedi E et al: High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 2005; 28: 1201.
30. Ansong KS, Lewis C, Jenkins P et al: Epidemiology of erectile dysfunction: a community-based study in rural New York state. Ann Epidemiol 2000; 10: 293.
31. Nwanko T, Yoon S, Burt V et al: Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. Hyattsville, MD: National Center for Health Statistics 2013.
32. Selvin E, Burnett AL and Platz EA: Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007; 120: 151.
33. Seftel AD, Sun P and Swindle R: The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171: 2341.
34. Rosen RC, Fisher WA, Eardley I et al: The Multinational Men's Attitudes to Life Events and Sexuality (MALES) Study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20: 607.
35. Manolis A and Doumas M: Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications. J Hypertens 2008; 26: 2074.
36. Toth PP, Potter D and Ming EE: Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol 2012; 6: 325.
37. Eaton CB, Liu YL, Mittleman MA et al: A retrospective study of the relationship between biomarkers of atherosclerosis and erectile dysfunction in 988 men. Int J Impot Res 2007; 19: 218.
38. Romeo JH, Seftel AD, Madhun ZT et al: Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000; 163: 788.
39. Bacon CG, Hu FB, Giovannucci E et al: Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002; 25: 1458.
40. Braun MH, Sommer F, Haupt G et al: Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "aging male" symptoms? Results of the "Cologne Male Survey." Eur Urol 2003; 44: 588.
41. Hoesl CE, Woll EM, Burkart M et al: Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol 2005; 47: 511.
42. Rosen R, Altwein J, Boyle P et al: Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003; 44: 637.
43. Gonzalez RR and Kaplan SA: Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Expert Opin Drug Metab Toxicol 2006; 2: 609.
44. Kaplan HS: The new sex therapy: active treatment of sexual dysfunctions: Brunner/Mazel 1974.
45. Masters W, Johnson, V: Human sexual response. New York, NY: Little, Brown and Co. 1966.
46. Marwick C: Survey says patients expect little physician help on sex. JAMA 1999; 281: 2173.
47. Althof SE, Rosen RC, Perelman MA et al: Standard operating procedures for taking a sexual history. J Sex Med 2013; 10: 26.
48. Serefoglu EC, McMahon CG, Waldinger MD et al: An evidence-based unified definition of lifelong and acquired premature ejacul*tion: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature ejacul*tion. Sex Med 2014; 2: 41.
49. Lee JH, Ngengwe R, Jones P et al: Erectile dysfunction as a coronary artery disease risk equivalent. J Nucl Cardiol 2008; 15: 800.
50. Fillo J, Levcikova M, Ondrusova M et al: Importance of different grades of abdominal obesity on testosterone level, erectile dysfunction, and clinical coincidence. Am J Mens Health 2017; 11: 240.
51. Ghanem HM, Salonia A and Martin-Morales A: SOP: physical examination and laboratory testing for men with erectile dysfunction. J Sex Med 2013; 10: 108.
52. McCabe MP and Althof SE: A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man's inability to have sex? J Sex Med 2014; 11: 347.
53. Corona G, Petrone L, Mannucci E et al: Assessment of the relational factor in male patients consulting for sexual dysfunction: the concept of couple sexual dysfunction. J Androl 2006; 27: 795.
54. McCabe M, Althof SE, Assalian P et al: Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med 2010; 7: 327.
55. Jannini EA, Isidori AM, Aversa A et al: Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions. J Sex Med 2013; 10: 2359.
56. Althof SE, Buvat J, Gutkin SW et al: Sexual satisfaction in men with erectile dysfunction: correlates and potential predictors. J Sex Med 2010; 7: 203.
57. Mulhall JP, Goldstein I, Bushmakin AG et al: Validation of the erection hardness score. J Sex Med 2007; 4: 1626.
58. Rosen RC, Cappelleri JC, Smith MD et al: Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319.
59. Rosen RC, Riley A, Wagner G et al: The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822.
60. Cappelleri JC, Rosen RC, Smith MD et al: Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346.
61. Rosen RC, Allen KR, Ni X et al: Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol 2011; 60: 1010.
62. Rosen RC, Catania J, Pollack L et al: Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology 2004; 64: 777.
63. Rosen RC, Catania JA, Althof SE et al: Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejacul*tory dysfunction. Urology 2007; 69: 805.
64. Dong JY, Zhang YH and Qin LQ: Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011; 58: 1378.
65. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK et al: Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013; 6: 99.
66. Thompson IM, Tangen CM, Goodman PJ et al: Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2996.
67. Montorsi P, Ravagnani PM, Galli S et al: Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: The COBRA trial. Eur Heart J 2006; 27: 2632.
68. Hotaling JM, Walsh TJ, Macleod LC et al: Erectile dysfunction is not independently associated with cardiovascular death: data from the Vitamins and Lifestyle (VITAL) Study. J Sex Med 2012; 9: 2104.
69. Nehra A, Jackson G, Miner M et al: The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87: 766.
70. Hippisley-Cox J, Coupland C and Brindle P: Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017; 357: j2099.
71. Dahabreh IJ and Paulus JK: Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis. JAMA 2011; 305: 1225.
72. Wu FC, Tajar A, Beynon JM et al: Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123.
73. Brambilla DJ, O'Donnell AB, Matsumoto AM et al: Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf) 2007; 67: 853.
74. Brambilla DJ, Matsumoto AM, Araujo AB et al: The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab 2009; 94: 907.
75. Welliver RC, Jr., Wiser HJ, Brannigan RE et al: Validity of midday total testosterone levels in older men with erectile dysfunction. J Urol 2014; 192: 165.
76. Woolf PD, Hamill RW, McDonald JV et al: Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab 1985; 60: 444.
77. Birthi P, Nagar VR, Nickerson R et al: Hypogonadism associated with long-term opioid therapy: a systematic review. J Opioid Manag 2015; 11: 255.
78. Elhanbly S and Elkholy A: Nocturnal penile erections: the role of Rigiscan in the diagnosis of vascular erectile dysfunction. J Sex Med 2012; 9: 3219.
79. Jannini EA, Granata AM, Hatzimouratidis K et al: Use and abuse of Rigiscan in the diagnosis of erectile dysfunction. J Sex Med 2009; 6: 1820.
80. Sikka SC, Hellstrom WJ, Brock G et al: Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med 2013; 10: 120.
81. Vruggink PA, Diemont WL, Debruyne FM et al: Enhanced pharmacological testing in patients with erectile dysfunction. J Androl 1995; 16: 163.
82. Diederichs W, Stief CG, Lue TF et al: Sympathetic inhibition of papaverine induced erection. J Urol 1991; 146: 195.
83. Elhanbly S, Schoor R, Elmogy M et al: What nonresponse to intracavernous injection really indicates: a determination by quantitative analysis. J Urol 2002; 167: 192.
84. Lehmann K, John H, Kacl G et al: Variable response to intracavernous prostaglandin E1 testing for erectile dysfunction. Urology 1999; 54: 539.
85. Souper R, Hartmann J, Alvarez M et al: Correlation between peak systolic velocity and diameter of cavernosal arteries in flaccid versus dynamic state for the evaluation of erectile dysfunction. Int J Impot Res 2017; 29: 132.
86. Papagiannopoulos D, Khare N and Nehra A: Evaluation of young men with organic erectile dysfunction. Asian J Androl 2015; 17: 11.
87. Ioakeimidis N, Vlachopoulos C, Rokkas K et al: Dynamic penile peak systolic velocity predicts major adverse cardiovascular events in hypertensive patients with erectile dysfunction. J Hypertens 2016; 34: 860.
88. Spiliopoulos S, Shaida N, Katsanos K et al: The role of interventional radiology in the diagnosis and management of male impotence. Cardiovasc Intervent Radiol 2013; 36: 1204.
89. Giuliano F and Rowland DL: Standard operating procedures for neurophysiologic assessment of male sexual dysfunction. J Sex Med 2013; 10: 1205.
90. Banner LL and Anderson RU: Integrated sildenafil and cognitive-behavior sex therapy for psychogenic erectile dysfunction: a pilot study. J Sex Med 2007; 4: 1117.
91. Melnik T, Abdo CH, de Moraes JF et al: Satisfaction with the treatment, confidence and 'naturalness' in engaging in sexual activity in men with psychogenic erectile dysfunction: preliminary results of a randomized controlled trial of three therapeutic approaches. BJU Int 2012; 109: 1213.
92. Titta M, Tavolini IM, Dal Moro F et al: Sexual counseling improved erectile rehabilitation after non-nerve-sparing radical retropubic prostatectomy or cystectomy--results of a randomized prospective study. J Sex Med 2006; 3: 267.
93. Wylie KR, Jones RH and Walters S: The potential benefit of vacuum devices augmenting psychosexual therapy for erectile dysfunction: a randomized controlled trial. J Sex Marital Ther 2003; 29: 227.
94. McCabe MP, Price E, Piterman L et al: Evaluation of an internet-based psychological intervention for the treatment of erectile dysfunction. Int J Impot Res 2008; 20: 324.
95. van Lankveld JJ, Leusink P, van Diest S et al: Internet-based brief sex therapy for heterosexual men with sexual dysfunctions: a randomized controlled pilot trial. J Sex Med 2009; 6: 2224.
96. Andersson E, Walen C, Hallberg J et al: A randomized controlled trial of guided internet-delivered cognitive behavioral therapy for erectile dysfunction. J Sex Med 2011; 8: 2800.
97.Melnik T, Soares BG and Nasello AG: The effectiveness of psychological interventions for the treatment of erectile dysfunction: systematic review and meta-analysis, including comparisons to sildenafil treatment, intracavernosal injection, and vacuum devices. J Sex Med 2008; 5: 2562. 98. Chambers SK, Occhipinti S, Schover L et al: A randomised controlled trial of a couples-based sexuality intervention for men with localised prostate cancer and their female partners. Psychooncology 2015; 24: 748.
99. Ljunggren C and Stroberg P: Improvement in sexual function after robot-assisted radical prostatectomy: a rehabilitation program with involvement of a clinical sexologist. Cent European J Urol 2015; 68: 214.
100. Esposito K, Giugliano F, Di Palo C et al: Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291: 2978.
101. Esposito K, Ciotola M, Giugliano F et al: Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 2006; 18: 405.
102. Esposito K, Ciotola M, Giugliano F et al: Effects of intensive lifestyle changes on erectile dysfunction in men. J Sex Med 2009; 6: 243.
103. Collins CE, Jensen ME, Young MD et al: Improvement in erectile function following weight loss in obese men: the SHED-IT randomized controlled trial. Obes Res Clin Pract 2013; 7: e450.
104. Khoo J, Piantadosi C, Worthley S et al: Effects of a low-energy diet on sexual function and lower urinary tract symptoms in obese men. Int J Obes (Lond) 2010; 34: 1396.
105. Khoo J, Tian HH, Tan B et al: Comparing effects of low- and high-volume moderate-intensity exercise on sexual function and testosterone in obese men. J Sex Med 2013; 10: 1823.
106. Wing RR, Rosen RC, Fava JL et al: Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look Ahead Trial. J Sex Med 2010; 7: 156.
107. Lamina S, Okoye CG and Dagogo TT: Therapeutic effect of an interval exercise training program in the management of erectile dysfunction in hypertensive patients. J Clin Hypertens (Greenwich) 2009; 11: 125.
108. Begot I, Peixoto TC, Gonzaga LR et al: A home-based walking program improves erectile dysfunction in men with an acute myocardial infarction. Am J Cardiol 2015; 115: 571.
109. Kalka D, Domagala Z, Dworak J et al: Association between physical exercise and quality of erection in men with ischaemic heart disease and erectile dysfunction subjected to physical training. Kardiol Pol 2013; 71: 573.
110. Kalka D, Domagala ZA, Kowalewski P et al: Effect of endurance cardiovascular training intensity on erectile dysfunction severity in men with ischemic heart disease. Am J Mens Health 2015; 9: 360.
111. Kovac JR, Labbate C, Ramasamy R et al: Effects of cigarette smoking on erectile dysfunction. Andrologia 2015; 47: 1087.
112. Afif-Abdo J, Teloken C, Damiao R et al: Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. BJU Int 2008; 102: 829.
113. Ali ST: Effectiveness of sildenafil citrate (Viagra®) and tadalafil (Cialis®) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice. Pak J Pharm Sci 2008; 21: 275.
114. Althof SE, O'Leary M P, Cappelleri JC et al: Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: results from an international, multi-center, double-blind, placebo-controlled trial. J Sex Med 2006; 3: 521.
115. Bai WJ, Li HJ, Dai YT et al: An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naive to phosphodiesterase 5 inhibitor therapy. Asian J Androl 2015; 17: 61.
116. Bai WJ, Li HJ, Jin JJ et al: A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction. Asian J Androl 2016;
117. Basar M, Tekdogan UY, Yilmaz E et al: The efficacy of sildenafil in different etiologies of erectile dysfunction. Int Urol Nephrol 2001; 32: 403.
118. Becher E, Tejada Noriega A, Gomez R et al: Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. Int J Impot Res 2002; 14 Suppl 2: S33.
119. Belkoff LH, McCullough A, Goldstein I et al: An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. Int J Clin Pract 2013; 67: 333.
120. Benard F, Carrier S, Lee JC et al: Men with mild erectile dysfunction benefit from sildenafil treatment. J Sex Med 2010; 7: 3725.
121. Benchekroun A, Faik M, Benjelloun S et al: A baseline-controlled, open-label, flexible dose-escalation study to assess the safety and efficacy of sildenafil citrate (Viagra) in patients with erectile dysfunction. Int J Impot Res 2003; 15 Suppl 1: S19.
122. Boddi V, Castellini G, Casale H et al: An integrated approach with vardenafil orodispersible tablet and cognitive behavioral sex therapy for treatment of erectile dysfunction: a randomized controlled pilot study. Andrology 2015; 3: 909.
123. Brock G, Carrier S, Alarie P et al: The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial. J Sex Med 2008; 5: 705.
124. Brock GB, McMahon CG, Chen KK et al: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332.
125. Buvat J, Hatzichristou D, Maggi M et al: Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction. BJU Int 2008; 102: 1645.
126. Buvat J, Buttner H, Hatzimouratidis K et al: Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. J Sex Med 2013; 10: 1592.
127. Hatzimouratidis K, Buvat J, Buttner H et al: Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. Int J Impot Res 2014; 26: 223.
128. Buvat J, Hatzichristou D, Boess FG et al: Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE Study. Int J Clin Pract 2014; 68: 1087.
129. Carrier S, Brock G, Casey R et al: Treatment satisfaction with sildenafil in a Canadian real-life setting. A 6-month prospective observational study of primary care practices. J Sex Med 2007; 4: 1414.
130. Carrier S, Brock GB, Pommerville PJ et al: Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. J Sex Med 2005; 2: 685.
131. Carson C, Shabsigh R, Segal S et al: Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology 2005; 65: 353.
132. Carson CC, Rajfer J, Eardley I et al: The efficacy and safety of tadalafil: an update. BJU Int 2004; 93: 1276.
133. Chen KK, Hsieh JT, Huang ST et al: ASSESS-3: a randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. Int J Impot Res 2001; 13: 221.
134. Chen KK, Jiann BP, Lin JS et al: Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study. J Sex Med 2004; 1: 201.
135. Cheng E: Real-life safety and efficacy of vardenafil in the treatment of erectile dysfunction-results from 30,010 US patients. J Sex Med 2007; 4: 432.
136. Choi HK, Ahn TY, Kim JJ et al: A double-blind, randomised- placebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea. Int J Impot Res 2003; 15: 80.
137. Choi HK, Kim JJ, Kim SC et al: A randomised, double-blind, parallel, placebo-controlled study of the efficacy and safety of tadalafil administered on-demand to men with erectile dysfunction in Korea. Korean J Urol 2006; 47: 852.
138. Christiansen E, Guirguis WR, Cox D et al: Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int J Impot Res 2000; 12: 177.
139. Costa P, Buvat J, Holmes S et al: Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens. J Sex Med 2006; 3: 1050.
140. Mirone V, Costa P, Damber JE et al: An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 2005; 47: 846.
141. Costa P, Grandmottet G, Mai HD et al: Impact of a first treatment with phosphodiesterase inhibitors on men and partners' quality of sexual life: results of a prospective study in primary care. J Sex Med 2013; 10: 1850.
142. Dean J, Hackett GI, Gentile V et al: Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006; 3: 650.
143. Eardley I, Mirone V, Montorsi F et al: An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323.
144. Dinsmore WW, Hodges M, Hargreaves C et al: Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 1999; 53: 800.
145. Donatucci C, Eardley I, Buvat J et al: Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification. J Sex Med 2004; 1: 301.
146. Eardley I, Gentile V, Austoni E et al: Efficacy and safety of tadalafil in a western European population of men with erectile dysfunction. BJU Int 2004; 94: 871.
147. Eardley I, Morgan R, Dinsmore W et al: Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction. Br J Psychiatry 2001; 178: 325.
148. Eardley I, Wright P, MacDonagh R et al: An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004; 93: 1271.
149. Edwards D, Hackett G, Collins O et al: Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): a randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naive men with ED and their partners. J Sex Med 2006; 3: 1028.
150. El Khiat Y, Ghazi S, Allam A et al: Psychosocial impact and effectiveness of tadalafil among treatment-naive and previously-treated men with erectile dysfunction in Saudi Arabia and other Gulf-region countries. Curr Med Res Opin 2008; 24: 1965.
151. fa*gelman E, fa*gelman A and Shabsigh R: Efficacy, safety, and use of sildenafil in urologic practice. Urology 2001; 57: 1141.
152. Zonana Farca E, Francolugo-Velez V, Moy-Eransus C et al: Self-esteem, confidence and relationship satisfaction in men with erectile dysfunction: a randomized, parallel-group, double-blind, placebo-controlled study of sildenafil in Mexico. Int J Impot Res 2008; 20: 402.
153. Fisher WA, Rosen RC, Mollen M et al: Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005; 2: 699.
154. Goldstein I, Fisher WA, Sand M et al: Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled trial. J Sex Med 2005; 2: 819.
155. Fugl-Meyer KS, Stothard D, Belger M et al: The effect of tadalafil on psychosocial outcomes in Swedish men with erectile distress: a multicentre, non-randomised, open-label clinical study. Int J Clin Pract 2006; 60: 1386.
156. Fujisawa M and Sawada K: Clinical efficacy and safety of sildenafil in elderly patients with erectile dysfunction. Arch Androl 2004; 50: 255.
157. Giammusso B, Colpi GM, Cormio L et al: An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. Urol Int 2008; 81: 409.
158. Gil A, Martinez E, Oyaguez I et al: Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. Int J Impot Res 2001; 13: 338.
159. Gittelman M, McMahon CG, Rodriguez-Rivera JA et al: The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int J Clin Pract 2010; 64: 594.
160. Giuliano F, Donatucci C, Montorsi F et al: Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int 2005; 95: 110.
161. Giuliano F, Montorsi F, Mirone V et al: Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. The Sildenafil Multicenter Study Group. J Urol 2000; 164: 708.
162. Glina S, Bertero E, Claro J et al: Efficacy and safety of flexible-dose oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction in Brazilian and Mexican men. Int J Impot Res 2002; 14 Suppl 2: S27.
163. Glina S, Damiao R, Abdo C et al: Self-esteem, confidence, and relationships in Brazilian men with erectile dysfunction receiving sildenafil citrate: a randomized, parallel-group, double-blind, placebo-controlled study in Brazil. J Sex Med 2009; 6: 268.
164. Cairoli C, Reyes LA, Henneges C et al: PDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational study. Int Braz J Urol 2014; 40: 390.
165. Gokce MI, Gulpinar O, Ozturk E et al: Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study. Int Urol Nephrol 2012; 44: 683.
166. Goldstein I, Kim E, Steers WD et al: Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J Sex Med 2007; 4: 166.
167. Goldstein I, McCullough AR, Jones LA et al: A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med 2012; 9: 1122.
168. Goldstein I, Lue TF, Padma-Nathan H et al: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397.
169. Goldstein I, Tseng LJ, Creanga D et al: Efficacy and safety of sildenafil by age in men with erectile dysfunction. J Sex Med 2016; 13: 852.
170. Gomez F, Davila H, Costa A et al: Efficacy and safety of oral sildenafil citrate (Viagra) in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: a double-blind, multicenter, placebo-controlled study. Int J Impot Res 2002; 14 Suppl 2: S42.
171. Govier F, Potempa AJ, Kaufman J et al: A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25: 2709.
172. Guo YL, Zhu JC, Pan TM et al: Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men. Int J Urol 2006; 13: 721.
173. Hartmann U, Hanisch JU and Mattern A: The real-life perception of efficacy, attitude, satisfaction and safety of vardenafil therapy (REPEAT): a prospective, non-interventional, observational study. Aging Male 2014; 17: 117.
174. Hatzichristou D, Cuzin B, Martin-Morales A et al: Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction. J Sex Med 2005; 2: 109.
175. Hatzichristou D, Montorsi F, Buvat J et al: The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men. Eur Urol 2004; 45: 634.
176. Hatzichristou D, Vardi Y, Papp G et al: Effect of tadalafil on sexual timing behavior patterns in men with erectile dysfunction: integrated analysis of randomized, placebo controlled trials. J Urol 2005; 174: 1356.
177. Heiman JR, Talley DR, Bailen JL et al: Sexual function and satisfaction in heterosexual couples when men are administered sildenafil citrate (Viagra) for erectile dysfunction: a multicentre, randomised, double-blind, placebo-controlled trial. Bjog 2007; 114: 437.
178. Hellstrom WJ, Gittelman M, Karlin G et al: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763.
179. Hellstrom WJ, Gittelman M, Karlin G et al: Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61: 8.
180. Huang ST: Use of sildenafil citrate in treatment of Taiwanese men with erectile dysfunction: a single center experience. Chang Gung Med J 2001; 24: 91.
181. Hundertmark J, Esterman A, Ben-Tovim D et al: The South Australian couples sildenafil study: double-blind, parallel-group randomized controlled study to examine the psychological and relationship consequences of sildenafil use in couples. J Sex Med 2007; 4: 1126.
182. Isidori AM, Corona G, Aversa A et al: The SIAMS-ED trial: a national, independent, multicentre study on cardiometabolic and hormonal impairment of men with erectile dysfunction treated with vardenafil. Int J Endocrinol 2014; 2014: doi:10.1155/2014/858715.
183. Jamshidian H, Borhan A, Kooraki S et al: Evaluation of the efficacy of once-daily use of tadalafil vs. on-demand use. Is there a cumulative effect? J Pak Med Assoc 2012; 62: 1195.
184. Jannini EA, Isidori AM, Gravina GL et al: The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med 2009; 6: 2547.
185. Jarow JP, Burnett AL and Geringer AM: Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722.
186. Jarvi K, Dula E, Drehobl M et al: Daily vardenafil for 6 months has no detrimental effects on sem*n characteristics or reproductive hormones in men with normal baseline levels. J Urol 2008; 179: 1060.
187. Jiann BP, Yu CC, Tsai JY et al: What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. Int J Impot Res 2003; 15: 412.
188. Jones LA, Klimberg IW, McMurray JG et al: Effect of sildenafil citrate on the male sexual experience assessed with the sexual experience questionnaire: a multicenter, double-blind, placebo-controlled trial with open-label extension. J Sex Med 2008; 5: 1955.
189. Kadioglu A, Grohmann W, Depko A et al: Quality of erections in men treated with flexible-dose sildenafil for erectile dysfunction: multicenter trial with a double-blind, randomized, placebo-controlled phase and an open-label phase. J Sex Med 2008; 5: 726.
190. Kamalov AA, Dorofeev SD, Efremov EA et al: The Russian experience of studying vardenafil efficacy and safety in men with erectile dysfunction of various aetiologies. Journal of Men's Health 2008; 5: 36.
191. Kamel A, Khaouli R, Sabha M et al: The real-life safety and efficacy of vardenafil: an international post-marketing surveillance study of 2824 patients from the Middle East. Clin Drug Investig 2007; 27: 339.
192. Kang DH, Lee JY, Park SY et al: Efficacy and safety of tadalafil 5 mg administered once daily in Korean men with erectile dysfunction: a prospective, multicenter study. Korean J Urol 2010; 51: 647.
193. Kang DH, Lee JY, Chung JH et al: Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. Int J Clin Pract 2012; 66: 813.
194. Kim E, Seftel A, Goldfischer E et al: Efficacy of as needed PDE5 inhibitor therapy vs. tadalafil once daily on improvement in erectile dysfunction. J Sex Med 2014; 11: 176.
195. Seftel AD, Rosen RC, Hayes RP et al: Effect of once-daily tadalafil on confidence and perceived difficulty in performing sexual intercourse in men who were incomplete responders to as-needed PDE5 inhibitor treatment. Int J Clin Pract 2014; 68: 841.
196. Kim E, Seftel A, Goldfischer E et al: Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. Curr Med Res Opin 2015; 31: 379.
197. Burns PR, Rosen RC, Dunn M et al: Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily. J Sex Med 2015; 12: 720.
198. Kim CM, Kim YS, Sunwoo S et al: Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care. Int J Impot Res 2007; 19: 393.
199. Kirby M, Creanga DL and Stecher VJ: Erectile function, erection hardness and tolerability in men treated with sildenafil 100 mg vs. 50 mg for erectile dysfunction. Int J Clin Pract 2013; 67: 1034.
200. Kobayashi K, Hisasue S, Kato R et al: Outcome analysis of sildenafil citrate for erectile dysfunction of Japanese patients. Int J Impot Res 2006; 18: 302.
201. Kongkanand A, Ratana-Olarn K, Ruangdilokrat S et al: The efficacy and safety of oral sildenafil in Thai men with erectile dysfunction: a randomized, double-blind, placebo controlled, flexible-dose study. J Med Assoc Thai 2003; 86: 195.
202. Koulikov D, Fridmans A, Chertin B et al: Is sildenafil citrate associated with an amelioration of the symptomatology of androgen decline in the aging male? J Urol 2007; 177: 2267.
203. Kumar S, Roat R, Agrawal S et al: Combination therapy of tadalafil and pentoxifylline in severe erectile dysfunction: a prospective randomized trial. Pol Przegl Chir 2015; 87: 377.
204. Levinson IP, Khalaf IM, Shaeer KZ et al: Efficacy and safety of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in Egypt and South Africa. Int J Impot Res 2003; 15 Suppl 1: S25.
205. Lewis R, Bennett CJ, Borkon WD et al: Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology 2001; 57: 960.
206. Li G, Lan H, Liang J et al: Efficacy of tadalafil de-escalation in the treatment of psychogenic erectile dysfunction. Urol Int 2017; 98: 205.
207. Lim PH, Li MK, Ng FC et al: Clinical efficacy and safety of sildenafil citrate (Viagra) in a multi-racial population in Singapore: a retrospective study of 1520 patients. Int J Urol 2002; 9: 308.
208. Loran OB, Stroberg P, Lee SW et al: Sildenafil citrate 100 mg starting dose in men with erectile dysfunction in an international, double-blind, placebo-controlled study: effect on the sexual experience and reducing feelings of anxiety about the next intercourse attempt. J Sex Med 2009; 6: 2826.
209. Magoha GA: Sildenafil (Viagra) in the treatment of male erectile dysfunction in Nairobi. East Afr Med J 2000; 77: 76.
210. Marks LS, Duda C, Dorey FJ et al: Treatment of erectile dysfunction with sildenafil. Urology 1999; 53: 19.
211. Martin-Morales A, Graziottin A, Jaoude GB et al: Improvement in sexual quality of life of the female partner following vardenafil treatment of men with erectile dysfunction: a randomized, double-blind, placebo-controlled study. J Sex Med 2011; 8: 2831.
212. Martin-Morales A, Gutierrez-Hernandez P, Romero-Otero J et al: Duration of erection: does it really matter? A randomized, double-blind clinical trial to assess the impact of vardenafil ODT on duration of erection and its correlation with patients' and partners' sexual quality of life and duration of intercourse: the VADEOPEN study. J Sex Med 2014; 11: 1527.
213. Martin-Morales A, Haro JM, Beardsworth A et al: Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). Eur Urol 2007; 51: 541.
214. Martin-Morales A, Meijide F, Garcia N et al: Efficacy of vardenafil and influence on self-esteem and self-confidence in patients with severe erectile dysfunction. J Sex Med 2007; 4: 440.
215. Martinez-Jabaloyas JM, Gil-Salom M, Villamon-Fort R et al: Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol 2001; 40: 641.
216. McMahon CG, Samali R and Johnson H: Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J Urol 2000; 164: 1192.
217. McMahon C, Kloner RA, Hutter Jr AM et al: Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005; 2: 415.
218. McMahon C, Lording D, Stuckey B et al: Vardenafil improved erectile function in a "real-life" broad population study of men with moderate to severe erectile dysfunction in Australia and New Zealand. J Sex Med 2006; 3: 892.
219. McMahon CG, Stuckey BG, Lording DW et al: A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men. Int J Clin Pract 2005; 59: 143.
220. McMurray JG, Feldman RA, Auerbach SM et al: Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag 2007; 3: 975.
221. Meuleman E, Cuzin B, Opsomer RJ et al: A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int 2001; 87: 75.
222. Mirone V, Palmieri A, Cucinotta D et al: Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction: a 12-week open-label, multicenter trial. J Sex Med 2005; 2: 842.
223. Moncada I, Martinez-Jabaloyas JM, Rodriguez-Vela L et al: Emotional changes in men treated with sildenafil citrate for erectile dysfunction: a double-blind, placebo-controlled clinical trial. J Sex Med 2009; 6: 3469.
224. Montorsi F and Althof SE: Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. Urology 2004; 63: 762.
225. Montorsi F, Aversa A, Moncada I et al: A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naive to PDE5 inhibitors. J Sex Med 2011; 8: 2617.
226. Porst H, Brock GB, Kula K et al: Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. J Androl 2012; 33: 1305.
227. Montorsi F, Hellstrom WJ, Valiquette L et al: Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology 2004; 64: 1187.
228. Montorsi F, McDermott TE, Morgan R et al: Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999; 53: 1011.
229. Montorsi F, Padma-Nathan H, Buvat J et al: Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. J Sex Med 2004; 1: 168.
230. Montorsi F, Verheyden B, Meuleman E et al: Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45: 339.
231. Moreira SG, Jr., Brannigan RE, Spitz A et al: Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 2000; 56: 474.
232. Morgentaler A, Barada J, Niederberger C et al: Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: use of a novel noninferiority study design. J Sex Med 2006; 3: 492.
233. Gomery P, Bullock A, McGettigan J et al: Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: results from multiple observations in men with erectile dysfunction in national tadalafil study in the US (MOMENTUS). Int J Impot Res 2007; 19: 76.
234. Muller A, Smith L, Parker M et al: Analysis of the efficacy and safety of sildenafil citrate in the geriatric population. BJU Int 2007; 100: 117.
235. Nagao K, Ishii N, Kamidono S et al: Safety and efficacy of vardenafil in patients with erectile dysfunction: result of a bridging study in Japan. Int J Urol 2004; 11: 515.
236. Nagao K, Kimoto Y, Marumo K et al: Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. Urology 2006; 68: 845.
237. O'Leary MP, Althof SE, Cappelleri JC et al: Self-esteem, confidence and relationship satisfaction of men with erectile dysfunction treated with sildenafil citrate: a multicenter, randomized, parallel group, double-blind, placebo controlled study in the United States. J Urol 2006; 175: 1058.
238. Ochiai A, Naya Y, Soh J et al: Efficacy of sildenafil as the first-step therapeutic tool for Japanese patients with erectile dysfunction. Int J Impot Res 2005; 17: 339.
239. Olsson AM, Speakman MJ, Dinsmore WW et al: Sildenafil citrate (Viagra) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology. Int J Clin Pract 2000; 54: 561.
240. Osegbe DN, sh*ttu OB, Aghaji AE et al: Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in Nigerian men. Int J Impot Res 2003; 15 Suppl 1: S15.
241. Padma-Nathan H, McMurray JG, Pullman WE et al: On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001; 13: 2.
242. Padma-Nathan H, Steers WD and Wicker PA: Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract 1998; 52: 375.
243. Palumbo F, Bettocchi C, Selvaggi FP et al: Sildenafil: efficacy and safety in daily clinical experience. Eur Urol 2001; 40: 176.
244. Pavone C, Curto F, Anello G et al: Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol 2004; 172: 2347.
245. Perimenis P, Gyftopoulos K, Giannitsas K et al: A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int J Impot Res 2004; 16: 2.
246. Perimenis P, Markou S, Gyftopoulos K et al: Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. Andrologia 2004; 36: 106.
247. Porst H, Behre HM, Jungwirth A et al: Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction--an open, randomized cross-over study with flexible dosing. Eur J Med Res 2007; 12: 61.
248. Porst H, Gacci M, Buttner H et al: Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol 2014; 65: 455.
249. Porst H, Giuliano F, Glina S et al: Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50: 351.
250. Porst H, Rajfer J, Casabe A et al: Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008; 5: 2160.
251. Porst H, Rosen R, Padma-Nathan H et al: The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192.
252. Porst H, Sharlip ID, Hatzichristou D et al: Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. Eur Urol 2006; 50: 1086.
253. Potempa AJ, Ulbrich E, Bernard I et al: Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study. Eur Urol 2004; 46: 73.
254. Rajfer J, Aliotta PJ, Steidle CP et al: Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007; 19: 95.
255. Ralph D, Eardley I, Kell P et al: Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int 2007; 100: 130.
256. Rosen R, Janssen E, Wiegel M et al: Psychological and interpersonal correlates in men with erectile dysfunction and their partners: a pilot study of treatment outcome with sildenafil. J Sex Marital Ther 2006; 32: 215.
257. Rosenberg MT, Adams PL, McBride TA et al: Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. Int J Clin Pract 2009; 63: 27.
258. Roumeguere T, Verheyden B, Arver S et al: Therapeutic response after first month of tadalafil treatment predicts 12 months treatment continuation in patients with erectile dysfunction: results from the detect study. J Sex Med 2008; 5: 1708.
259. Perimenis P, Roumeguere T, Heidler H et al: Evaluation of patient expectations and treatment satisfaction after 1-year tadalafil therapy for erectile dysfunction: the DETECT study. J Sex Med 2009; 6: 257.
260. Rubio-Aurioles E, Casabe A, Torres LO et al: Efficacy and safety of tadalafil in the treatment of Latin American men with erectile dysfunction: results of integrated analyses. J Sex Med 2008; 5: 1965.
261. Rubio-Aurioles E, Kim ED, Rosen RC et al: Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med 2009; 6: 1314.
262. Seftel AD, Buvat J, Althof SE et al: Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily. Int J Impot Res 2009; 21: 240.
263. Rubio-Aurioles E, Porst H, Kim ED et al: A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 2012; 9: 1418.
264. Sairam K, Kulinskaya E, Hanbury D et al: Oral sildenafil (Viagra) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital. BMC Urol 2002; 2: 4.
265. Saylan M, Khalaf I, Kadioglu A et al: Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction. Int J Clin Pract 2006; 60: 812.
266. Seftel AD, Creanga DL and Levinson IP: Sildenafil reduces bother associated with erectile dysfunction: pooled analysis of five randomized, double-blind trials. Int J Impot Res 2007; 19: 584.
267. Seftel AD, Wilson SK, Knapp PM et al: The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction. J Urol 2004; 172: 652.
268. Shabsigh R, Kaufman J, Magee M et al: A multicenter, double-blind, placebo-controlled trial to assess the efficacy of sildenafil citrate in men with unrecognized erectile dysfunction. Urology 2010; 76: 373.
269. Shin YS, Lee SW, Park K et al: Effect of Levitra on sustenance of erection (EROS): an open-label, prospective, multicenter, single-arm study to investigate erection duration measured by stopwatch with flexible dose vardenafil administered for 8 weeks in subjects with erectile dysfunction. Int J Impot Res 2015; 27: 95.
270. Skoumal R, Chen J, Kula K et al: Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004; 46: 362.
271. Sommer F, Klotz T and Engelmann U: Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl 2007; 9: 134.
272. Sperling H, Debruyne F, Boermans A et al: The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med 2010; 7: 1497.
273. Sperling H, Schneider T and Hanisch JU: Acceptance of therapy in vardenafil-treated patients with erectile dysfunction (ACTIVE): a noninterventional study in Germany. Int J Impot Res 2010; 22: 61.
274. Staab A, Tillmann C, Forgue ST et al: Population dose-response model for tadalafil in the treatment of male erectile dysfunction. Pharm Res 2004; 21: 1463.
275. Steers W, Guay AT, Leriche A et al: Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment. Int J Impot Res 2001; 13: 261.
276. Steidle CP, McCullough AR, Kaminetsky JC et al: Early sildenafil dose optimization and personalized instruction improves the frequency, flexibility, and success of sexual intercourse in men with erectile dysfunction. Int J Impot Res 2007; 19: 154.
277. Stief C, Porst H, Saenz De Tejada I et al: Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004; 58: 230.
278. Stroberg P, Murphy A and Costigan T: Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 2003; 25: 2724.
279. Sunwoo S, Kim YS, Cho BL et al: Post-marketing surveillance study of the safety and efficacy of sildenafil prescribed in primary care to erectile dysfunction patients. Int J Impot Res 2005; 17: 71.
280. Tan HM, Chin CM, Chua CB et al: Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction. Asian J Androl 2008; 10: 495.
281. Tan HM, Moh CL, Mendoza JB et al: Asian sildenafil efficacy and safety study (ASSESS-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. The ASSESS-1 study group. Urology 2000; 56: 635.
282. Tang WH, Zhuang XJ, Ma LL et al: Effect of sildenafil on erectile dysfunction and improvement in the quality of sexual life in China: a multi-center study. Int J Clin Exp Med 2015; 8: 11539.
283. Taylor J, Baldo OB, Storey A et al: Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int 2009; 103: 1392.
284. Tolra JR, Campana JM, Ciutat LF et al: Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006; 3: 901.
285. Tsujimura A, Yamanaka M, Takahashi T et al: The clinical studies of sildenafil for the ageing male. Int J Androl 2002; 25: 28.
286. Valiquette L, Montorsi F and Auerbach S: Vardenafil demonstrates first-dose success and reliability of penetration and maintenance of erection in men with erectile dysfunction - RELY-II. Can Urol Assoc J 2008; 2: 187.
287. Valiquette L, Young JM, Moncada I et al: Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2005; 80: 1291.
288. Van Ahlen H, Zumbe J, Stauch K et al: The real-life safety and efficacy of vardenafil (REALISE) study: results in men from Europe and overseas with erectile dysfunction and cardiovascular or metabolic conditions. J Sex Med 2010; 7: 3161.
289. Virag R: Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology 1999; 54: 1073.
290. von Keitz A, Rajfer J, Segal S et al: A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499.
291. Wagner G, Montorsi F, Auerbach S et al: Sildenafil citrate (Viagra) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 2001; 56: M113.
292. Wijitsettakul U and Pempongkosol S: The efficacy and safety of on-demand elonza; a generic product of sildenafil in Thai men with erectile dysfunction. J Med Assoc Thai 2013; 96: 683.
293. Yang Y, Liu R, Jiang H et al: Association between dosage frequency and the treatment outcomes of sildenafil in young and middle-aged men with erectile dysfunction: a Chinese, multicenter, observational study. Urology 2015; 86: 62.
294. Yip WC, Chiang HS, Mendoza JB et al: Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: a randomized double-blind, parallel, placebo-controlled clinical study. Asian J Androl 2006; 8: 685.
295. Young JM, Bennett C, Gilhooly P et al: Efficacy and safety of sildenafil citrate (Viagra) in black and Hispanic American men. Urology 2002; 60: 39.
296. Zhang K, Xu B, Liu D et al: Sildenafil improves erectile hardness in Chinese men with erectile dysfunction: a real-life study analyzed on age stratification. Urology 2014; 83: 831.
297. Zhao C, Kim SW, Yang DY et al: Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. BJU Int 2012; 110: 1801.
298. Zumbe J, Porst H, Sommer F et al: Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the restore study. Eur Urol 2008; 54: 204.
299. Park HJ, Kim SW, Kim JJ et al: A randomized, placebo-controlled, double-blind, multi-center therapeutic confirmatory study to evaluate the safety and efficacy of avanafil in Korean patients with erectile dysfunction. J Korean Med Sci 2017; 32: 1016.
300. Li HJ, Bai WJ, Dai YT et al: An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction. Asian J Androl 2016; 18: 773.
301. Bai WJ, Li HJ, Jin JJ et al: A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction. Asian J Androl 2017; 19: 500.
302. Capogrosso P, Ventimiglia E, Boeri L et al: Time of onset of vardenafil orodispersible tablet in a real-life setting - looking beyond randomized clinical trials. Expert Rev Clin Pharmacol 2017; 10: 339.
303. Karabakan M, Keskin E, Akdemir S et al: Effect of tadalafil 5mg daily treatment on the ejacul*tory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction. Int Braz J Urol 2017; 43: 317.
304. Gong B, Ma M, Xie W et al: Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol 2017; 49: 1731.
305. Bekkering GE, Abou-Setta AM and Kleijnen J: The application of quantitative methods for identifying and exploring the presence of bias in systematic reviews: PDE-5 inhibitors for erectile dysfunction. Int J Impot Res 2008; 20: 264.
306. Berner MM, Kriston L and Harms A: Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. Int J Impot Res 2006; 18: 229.
307. Chen L, Staubli SE, Schneider MP et al: Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol 2015; 68: 674.
308. Tsertsvadze A, Fink HA, Yazdi F et al: Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009; 151: 650.
309. Tsertsvadze A, Yazdi F, Fink HA et al: Oral sildenafil citrate (Viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. Urology 2009; 74: 831.
310. Yuan J, Zhang R, Yang Z et al: Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013; 63: 902.
311. Yuan JQ, Mao C, Yang ZY et al: A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. Asian J Androl 2016; 18: 60.
312. Burls A, Gold L and Clark W: Systematic review of randomised controlled trials of sildenafil (Viagra) in the treatment of male erectile dysfunction. Br J Gen Pract 2001; 51: 1004.
313. Fink HA, Mac Donald R, Rutks IR et al: Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002; 162: 1349.
314. Kriston L, Harms A and Berner MM: A meta-regression analysis of treatment effect modifiers in trials with flexible-dose oral sildenafil for erectile dysfunction in broad-spectrum populations. Int J Impot Res 2006; 18: 559.
315. Moore RA, Edwards JE and McQuay HJ: Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol 2002; 2: 6.
316. Peng Z, Yang L, Dong Q et al: Efficacy and safety of tadalafil once-a-day versus tadalafil on-demand in patients with erectile dysfunction: a systematic review and meta-analyses. Urol Int 2017; 99: 343.
317. Markou S, Perimenis P, Gyftopoulos K et al: Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. Int J Impot Res 2004; 16: 470.
318. Cui YS, Li N, Zong HT et al: Avanafil for male erectile dysfunction: a systematic review and meta-analysis. Asian J Androl 2014; 16: 472.
319. Wang H, Yuan J, Hu X et al: The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis. Curr Med Res Opin 2014; 30: 1565.
320. Behrend L, Vibe-Petersen J and Perrild H: Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. Int J Impot Res 2005; 17: 264.
321. Blonde L: Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. Curr Med Res Opin 2006; 22: 2111.
322. Boulton AJ, Selam JL, Sweeney M et al: Sildenafil citrate for the treatment of erectile dysfunction in men with type 2 diabetes mellitus. Diabetologia 2001; 44: 1296.
323. Burnett AL, Strong TD, Trock BJ et al: Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. J Urol 2009; 181: 245.
324. Buvat J, van Ahlen H, Schmitt H et al: Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. J Sex Med 2006; 3: 512.
325. Chen Y, Cui S, Lin H et al: Losartan improves erectile dysfunction in diabetic patients: a clinical trial. Int J Impot Res 2012; 24: 217.
326. Deyoung L, Chung E, Kovac JR et al: Daily use of sildenafil improves endothelial function in men with type 2 diabetes. J Androl 2012; 33: 176.
327. El-Sakka AI: Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol 2004; 46: 503.
328. El-Sakka AI, Anis T, Khadr N et al: Sildenafil for erectile dysfunction in the Middle East: observational analysis of patients with diabetes and/or hypertension treated in the clinical practice setting. J Int Med Res 2011; 39: 558.
329. Fonseca V, Seftel A, Denne J et al: Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004; 47: 1914.
330. Gentile V, Vicini P, Prigiotti G et al: Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin 2004; 20: 1377.
331. Goldstein I, Jones LA, Belkoff LH et al: Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc 2012; 87: 843.
332. Goldstein I, Young JM, Fischer J et al: Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26: 777.
333. Grover-Paez F, Villegas Rivera G and Guillen Ortiz R: Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 78: 136.
334. Hatzichristou D, Gambla M, Rubio-Aurioles E et al: Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008; 25: 138.
335. Ishii N, Nagao K, Fujikawa K et al: Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction. Int J Urol 2006; 13: 1066.
336. Kirilmaz U, Guzel O, Aslan Y et al: The effect of lifestyle modification and glycemic control on the efficiency of sildenafil citrate in patients with erectile dysfunction due to type-2 diabetes mellitus. Aging Male 2015; 18: 244.
337. Lee JW, Park HJ and Park NC: Serum high-sensitivity C-reactive protein levels and response to 5 mg tadalafil once daily in patients with erectile dysfunction and diabetes. Korean J Urol 2013; 54: 858.
338. Hamidi Madani A, Asadolahzade A, Mokhtari G et al: Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus. J Sex Med 2013; 10: 1146.
339. Morano S, Mandosi E, Fallarino M et al: Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur Urol 2007; 52: 1768.
340. Ng KK, Lim HC, Ng FC et al: The use of sildenafil in patients with erectile dysfunction in relation to diabetes mellitus--a study of 1,511 patients. Singapore Med J 2002; 43: 387.
341. Perimenis P, Markou S, Gyftopoulos K et al: Switching from long-term treatment with self-injections to oral sildenafil in diabetic patients with severe erectile dysfunction. Eur Urol 2002; 41: 387.
342. Popovic S, Nale D, Dabetic M et al: Effect of tadalafil on erectile dysfunction in male patients with diabetes mellitus. Vojnosanit Pregl 2007; 64: 399.
343. Price DE, Gingell JC, Gepi-Attee S et al: Sildenafil: Study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998; 15: 821.
344. Rendell MS, Rajfer J, Wicker PA et al: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999; 281: 421.
345. Saenz de Tejada I, Anglin G, Knight JR et al: Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25: 2159.
346. Safarinejad MR: Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complications 2004; 18: 205.
347. Santi D, Granata AR, Guidi A et al: Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. Eur J Endocrinol 2016; 174: 513.
348. Stuckey BG, Jadzinsky MN, Murphy LJ et al: Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003; 26: 279.
349. Zamorano-Leon JJ, Olivier C, de Las Heras N et al: Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin. J Sex Med 2013; 10: 3110.
350. Ziegler D, Merfort F, Van Ahlen H et al: Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006; 3: 883.
351. Maresca L, D'Agostino M, Castaldo L et al: Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors. Monaldi Arch Chest Dis 2013; 80: 177.
352. Schneider T, Gleissner J, Merfort F et al: Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial. J Sex Med 2011; 8: 2904.
353. Shabsigh R and Mattern A: REVITALISE: a large observational study assessing the safety and effectiveness of vardenafil in men with erectile dysfunction and metabolic syndrome. Sex Med 2016; 4: e135.
354. Suetomi T, Kawai K, Hinotsu S et al: Negative impact of metabolic syndrome on the responsiveness to sildenafil in Japanese men. J Sex Med 2008; 5: 1443.
355. Dadkhah F, Safarinejad MR, Asgari MA et al: Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res 2010; 22: 51.
356. Miner M, Gilderman L, Bailen J et al: Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008; 5: 1455.
357. Miner MM, Barnes A and Janning S: Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study. J Sex Med 2010; 7: 1937.
358. Albuquerque DC, Miziara LJ, Saraiva JF et al: Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs. Int Braz J Urol 2005; 31: 342.
359. Aranda P, Ruilope LM, Calvo C et al: Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens 2004; 17: 139.
360. Kloner RA, Brown M, Prisant LM et al: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001; 14: 70.
361. Kloner RA, Sadovsky R, Johnson EG et al: Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. Int J Impot Res 2005; 17: 450.
362. Park HJ, Park NC, Shim HB et al: An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents. J Sex Med 2008; 5: 2405.
363. Pickering TG, Shepherd AM, Puddey I et al: Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens 2004; 17: 1135.
364. van Ahlen H, Wahle K, Kupper W et al: Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005; 2: 856.
365. Freitas D, Athanazio R, Almeida D et al: Sildenafil improves quality of life in men with heart failure and erectile dysfunction. Int J Impot Res 2006; 18: 210.
366. Katz SD, Parker JD, Glasser DB et al: Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005; 95: 36.
367. Webster LJ, Michelakis ED, Davis T et al: Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med 2004; 164: 514.
368. Conti CR, Pepine CJ and Sweeney M: Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999; 83: 29c.
369. DeBusk RF, Pepine CJ, Glasser DB et al: Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004; 93: 147.
370. Bocchio M, Pelliccione F, Mihalca R et al: Treatment of erectile dysfunction reduces psychological distress. Int J Androl 2009; 32: 74.
371. Buranakitjaroen P, Mangklabruks A, Leungwattanakij S et al: Efficacy and safety of sildenafil in Asian males with erectile dysfunction and cardiovascular risk. J Med Assoc Thai 2007; 90: 1100.
372. Olsson AM and Persson CA: Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Pract 2001; 55: 171.
373. Rubio-Aurioles E, Porst H, Eardley I et al: Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 2006; 3: 1037.
374. Vicari E, Malaguarnera M, La Vignera S et al: Efficacy and limits of sildenafil citrate in patients with arterial erectile dysfunction: role of peripheral arterial disease and cardiovascular comorbidities. Asian J Androl 2008; 10: 847.
375. Abolyosr A, Elsagheer GA, Abdel-Kader MS et al: Evaluation of the effect of sildenafil and/or doxazosin on benign prostatic hyperplasia-related lower urinary tract symptoms and erectile dysfunction. Urol Ann 2013; 5: 237.
376. Choi H, Kim JH, Shim JS et al: Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms. Int J Impot Res 2015; 27: 33.
377. Egerdie RB, Auerbach S, Roehrborn CG et al: Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012; 9: 271.
378. Eryildirim B, Aktas A, Kuyumcuoglu U et al: The effectiveness of sildenafil citrate in patients with erectile dysfunction and lower urinary system symptoms and the significance of asymptomatic inflammatory prostatitis. Int J Impot Res 2010; 22: 349.
379. Giuliano F, Oelke M, Jungwirth A et al: Tadalafil once daily improves ejacul*tory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. J Sex Med 2013; 10: 857.
380. Jin Z, Zhang ZC, Liu JH et al: An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Asian J Androl 2011; 13: 630.
381. Kaplan SA, Gonzalez RR and Te AE: Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717.
382. Lee JY, Park SY, Jeong TY et al: Combined tadalafil and alpha-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study. J Androl 2012; 33: 397.
383. Liguori G, Trombetta C, De Giorgi G et al: Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 2009; 6: 544.
384. McVary KT, Kaufman J, Young JM et al: Sildenafil citrate improves erectile function: a randomised double-blind trial with open-label extension. Int J Clin Pract 2007; 61: 1843.
385. McVary KT, Monnig W, Camps JL, Jr. et al: Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071.
386. Mulhall JP, Guhring P, Parker M et al: Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662.
387. Porst H, McVary KT, Montorsi F et al: Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56: 727.
388. Porst H, Roehrborn CG, Secrest RJ et al: Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. J Sex Med 2013; 10: 2044.
389. Tuncel A, Nalcacioglu V, Ener K et al: Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 2010; 28: 17.
390. Maselli G, Bergamasco L, Silvestri V et al: Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study. Int J Urol 2011; 18: 515.
391. Yu H, Wu H and Rao D: Analysis of the therapeutic effect of tadalafil on male ED after transurethral resection of prostate. Int J Impot Res 2012; 24: 147.
392. Perimenis P, Karkoulias K, Markou S et al: Erectile dysfunction in men with obstructive sleep apnea syndrome: a randomized study of the efficacy of sildenafil and continuous positive airway pressure. Int J Impot Res 2004; 16: 256.
393. Perimenis P, Konstantinopoulos A, Karkoulias K et al: Sildenafil combined with continuous positive airway pressure for treatment of erectile dysfunction in men with obstructive sleep apnea. Int Urol Nephrol 2007; 39: 547.
394. Condorelli RA, Calogero AE, Di Mauro M et al: Effects of tadalafil treatment combined with physical activity in patients with low onset hypogonadism: results from a not-randomized single arm phase 2 study. Aging Male 2016; 3: 155.
395. Kennedy SH, Dugre H and Defoy I: A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder. Int Clin Psychopharmacol 2011; 26: 151.
396. Rosen R, Shabsigh R, Berber M et al: Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry 2006; 163: 79.
397. Seidman SN, Roose SP, Menza MA et al: Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001; 158: 1623.
398. Aizenberg D, Weizman A and Barak Y: Sildenafil for selective serotonin reuptake inhibitor-induced erectile dysfunction in elderly male depressed patients. J Sex Marital Ther 2003; 29: 297.
399. Evliyaoglu Y, Yelsel K, Kobaner M et al: Efficacy and tolerability of tadalafil for treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. Urology 2011; 77: 1137.
400. Fava M, Nurnberg HG, Seidman SN et al: Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2006; 67: 240.
401. Nurnberg HG, Fava M, Gelenberg AJ et al: Open-label sildenafil treatment of partial and non-responders to double-blind treatment in men with antidepressant-associated sexual dysfunction. Int J Impot Res 2007; 19: 167.
402. Nurnberg HG, Gelenberg A, Hargreave TB et al: Efficacy of sildenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. Am J Psychiatry 2001; 158: 1926.
403. Nurnberg HG, Hensley PL, Gelenberg AJ et al: Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 2003; 289: 56.
404. Segraves RT, Lee J, Stevenson R et al: Tadalafil for treatment of erectile dysfunction in men on antidepressants. J Clin Psychopharmacol 2007; 27: 62.
405. Tignol J, Furlan PM, Gomez-Beneyto M et al: Efficacy of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in remission from depression. Int Clin Psychopharmacol 2004; 19: 191.
406. Karami H, Hassanzadeh-Hadad A and Fallah-Karkan M: Comparing monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia: a randomized clinical trial. Urol J 2016; 13: 2920.
407. Ozcan L, Polat EC, Kocaaslan R et al: Effects of taking tadalafil 5 mg once daily on erectile function and total testosterone levels in patients with metabolic syndrome. Andrologia 2017; 49: e12751.
408. Lee LK, Goren A, Boytsov NN et al: Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations. Patient Prefer Adherence 2016; 10: 1205.
409. Bolat MS, Ozer I, Cinar O et al: The efficacy of low-dose tadalafil in patients undergoing hemodialysis with end-stage renal disease. Ren Fail 2017; 39: 582.
410. Azab S, Aoud H and Nabil N: The correlation between high sensitivity C-reactive protein and erectile dysfunction patients with hypertension treated with vardenafil. Int J Impot Res 2017; 29: 82.
411. Ohl DA, Carlsson M, Stecher VJ et al: Efficacy and safety of sildenafil in men with sexual dysfunction and spinal cord injury. Sex Med Rev 2017; 5: 521.
412. Bannowsky A, Schulze H, van der Horst C et al: Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int 2008; 101: 1279.
413. Bannowsky A, van Ahlen H and Loch T: Increasing the dose of vardenafil on a daily basis does not improve erectile function after unilateral nerve-sparing radical prostatectomy. J Sex Med 2012; 9: 1448.
414. Blander DS, Sanchez-Ortiz RF, Wein AJ et al: Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. Int J Impot Res 2000; 12: 165.
415. Briganti A, Di Trapani E, Abdollah F et al: Choosing the best candidates for penile rehabilitation after bilateral nerve-sparing radical prostatectomy. J Sex Med 2012; 9: 608.
416. Brock G, Nehra A, Lipshultz LI et al: Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170: 1278.
417. Canat L, Guner B, Gurbuz C et al: Effects of three-times-per-week versus on-demand tadalafil treatment on erectile function and continence recovery following bilateral nerve sparing radical prostatectomy: results of a prospective, randomized, and single-center study. Kaohsiung J Med Sci 2015; 31: 90.
418. Cathala N, Mombet A, Sanchez-Salas R et al: Evaluation of erectile function after laparoscopic radical prostatectomy in a single center. Can J Urol 2012; 19: 6328.
419. Cavallini G, Modenini F, Vitali G et al: Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology 2005; 66: 1080.
420. Feng MI, Huang S, Kaptein J et al: Effect of sildenafil citrate on post-radical prostatectomy erectile dysfunction. J Urol 2000; 164: 1935.
421. Hirik E, Bozkurt A, Karabakan M et al: Results of tadalafil treatment in patients following an open nerve-sparing radical prostatectomy. Arch Ital Urol Androl 2016; 88: 4.
422. Hubanks JM, Umbreit EC, Karnes RJ et al: Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series. Eur Urol 2012; 61: 878.
423. Kim DJ, Hawksworth DJ, Hurwitz LM et al: A prospective, randomized, placebo-controlled trial of on-demand vs. nightly sildenafil citrate as assessed by Rigiscan and the International Index of Erectile Function. Andrology 2016; 4: 27.
424. Kimura M, Caso JR, Banez LL et al: Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy. BJU Int 2012; 110: E931.
425. Lee IH, Sadetsky N, Carroll PR et al: The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors. J Urol 2008; 179: 1072.
426. Lowentritt BH, Scardino PT, Miles BJ et al: Sildenafil citrate after radical retropubic prostatectomy. J Urol 1999; 162: 1614.
427. McCullough AR, Hellstrom WG, Wang R et al: Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol 2010; 183: 2451.
428. Megas G, Papadopoulos G, Stathouros G et al: Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction. BJU Int 2013; 112: E169.
429. Montorsi F, Brock G, Lee J et al: Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54: 924.
430. Montorsi F, Brock G, Stolzenburg JU et al: Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). Eur Urol 2014; 65: 587.
431. Patel HR, Ilo D, Shah N et al: Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV study. BMC Urol 2015; 15: 31.
432. Montorsi F, Nathan HP, McCullough A et al: Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 2004; 172: 1036.
433. Mulhall JP, Burnett AL, Wang R et al: A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. J Urol 2013; 189: 2229.
434. Nakano Y, Miyake H, Chiba K et al: Impact of penile rehabilitation with low-dose vardenafil on recovery of erectile function in Japanese men following nerve-sparing radical prostatectomy. Asian J Androl 2014; 16: 892.
435. Nehra A, Grantmyre J, Nadel A et al: Vardenafil improved patient satisfaction with erectile hardness, org*smic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 2005; 173: 2067.
436. Ogura K, Ichioka K, Terada N et al: Role of sildenafil citrate in treatment of erectile dysfunction after radical retropubic prostatectomy. Int J Urol 2004; 11: 159.
437. Pace G, Del Rosso A and Vicentini C: Penile rehabilitation therapy following radical prostatectomy. Disabil Rehabil 2010; 32: 1204.
438. Padma-Nathan H, McCullough AR, Levine LA et al: Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20: 479.
439. Pavlovich CP, Levinson AW, Su LM et al: Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo. BJU Int 2013; 112: 844.
440. Raina R, Agarwal A, Allamaneni SS et al: Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology 2005; 65: 360.
441. Raina R, Lakin MM, Agarwal A et al: Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy. Urology 2004; 63: 532.
442. Raina R, Lakin MM, Agarwal A et al: Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 2004; 63: 960.
443. Raina R, Lakin MM, Agarwal A et al: Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology 2003; 62: 110.
444. Seo YE, Kim SD, Kim TH et al: The efficacy and safety of tadalafil 5 mg once daily in the treatment of erectile dysfunction after robot-assisted laparoscopic radical prostatectomy: 1-year follow-up. Korean J Urol 2014; 55: 112.
445. Zagaja GP, Mhoon DA, Aikens JE et al: Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology 2000; 56: 631.
446. Zippe CD, Jhaveri FM, Klein EA et al: Role of Viagra after radical prostatectomy. Urology 2000; 55: 241.
447. Zippe CD, Kedia AW, Kedia K et al: Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 1998; 52: 963.
448. Watkins Bruner D, James JL, Bryan CJ et al: Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. J Sex Med 2011; 8: 1228.
449. Harrington C, Campbell G, Wynne C et al: Randomised, placebo-controlled, crossover trial of sildenafil citrate in the treatment of erectile dysfunction following external beam radiation treatment of prostate cancer. J Med Imaging Radiat Oncol 2010; 54: 224.
450. Ilic D, Hindson B, duch*esne G et al: A randomised, double-blind, placebo-controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. J Med Imaging Radiat Oncol 2013; 57: 81.
451. Incrocci L, Hop WC and Slob AK: Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer. Urology 2003; 62: 116.
452. Incrocci L, Koper PC, Hop WC et al: Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys 2001; 51: 1190.
453. Incrocci L, Slagter C, Slob AK et al: A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 439.
454. Incrocci L, Slob AK and Hop WC: Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial. Urology 2007; 70: 1190.
455. Kedia S, Zippe CD, Agarwal A et al: Treatment of erectile dysfunction with sildenafil citrate (Viagra) after radiation therapy for prostate cancer. Urology 1999; 54: 308.
456. Merrick GS, Butler WM, Lief JH et al: Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. Urology 1999; 53: 1112.
457. Ohebshalom M, Parker M, Guhring P et al: The efficacy of sildenafil citrate following radiation therapy for prostate cancer: temporal considerations. J Urol 2005; 174: 258.
458. Pahlajani G, Raina R, Jones JS et al: Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function. BJU Int 2010; 106: 1524.
459. Pisansky TM, Pugh SL, Greenberg RE et al: Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the radiation therapy oncology group [0831] randomized clinical trial. JAMA 2014; 311: 1300.
460. Potters L, Torre T, Fearn PA et al: Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1235.
461. Raina R, Agarwal A, Goyal KK et al: Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. Urology 2003; 62: 1103.
462. Ricardi U, Gontero P, Ciammella P et al: Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. J Sex Med 2010; 7: 2851.
463. Schiff JD, Bar-Chama N, Cesaretti J et al: Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. BJU Int 2006; 98: 1255.
464. Shemtov OM, Radomski SB and Crook J: Success of sildenafil for erectile dysfunction in men treated with brachytherapy or external beam radiation for prostate cancer. Can J Urol 2004; 11: 2450.
465. Teloken PE, Ohebshalom M, Mohideen N et al: Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol 2007; 178: 2521.
466. Teloken PE, Parker M, Mohideen N et al: Predictors of response to sildenafil citrate following radiation therapy for prostate cancer. J Sex Med 2009; 6: 1135.
467. Valicenti RK, Choi E, Chen C et al: Sildenafil citrate effectively reverses sexual dysfunction induced by three-dimensional conformal radiation therapy. Urology 2001; 57: 769.
468. Weber DC, Bieri S, Kurtz JM et al: Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. J Clin Oncol 1999; 17: 3444.
469. Zelefsky MJ, McKee AB, Lee H et al: Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 1999; 53: 775.
470. Zelefsky MJ, Shasha D, Branco RD et al: Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer. J Urol 2014; 192: 868.
471. Chen J, Mabjeesh NJ, Greenstein A et al: Clinical efficacy of sildenafil in patients on chronic dialysis. J Urol 2001; 165: 819.
472. Hyodo T, Ishida H, Masui N et al: Kidney disease quality of life of Japanese dialysis patients who desire administration of sildenafil and the treatment of erectile dysfunction using sildenafil. Ther Apher Dial 2004; 8: 340.
473. Rosas SE, Wasserstein A, Kobrin S et al: Preliminary observations of sildenafil treatment for erectile dysfunction in dialysis patients. Am J Kidney Dis 2001; 37: 134.
474. Seibel I, Poli De Figueiredo CE, Teloken C et al: Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. J Am Soc Nephrol 2002; 13: 2770.
475. Tas A, Ersoy A, Ersoy C et al: Efficacy of sildenafil in male dialysis patients with erectile dysfunction unresponsive to erythropoietin and/or testosterone treatments. Int J Impot Res 2006; 18: 61.
476. Turk S, Karalezli G, Tonbul HZ et al: Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2001; 16: 1818.
477. Turk S, Solak Y, Kan S et al: Effects of sildenafil and vardenafil on erectile dysfunction and health-related quality of life in haemodialysis patients: a prospective randomized crossover study. Nephrol Dial Transplant 2010; 25: 3729.
478. YenicerioGlu Y, Kefi A, Aslan G et al: Efficacy and safety of sildenafil for treating erectile dysfunction in patients on dialysis. BJU Int 2002; 90: 442.
479. Barrou B, Cuzin B, Malavaud B et al: Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients. Nephrol Dial Transplant 2003; 18: 411.
480. Demir E, Balal M, Paydas S et al: Efficacy and safety of vardenafil in renal transplant recipients with erectile dysfunction. Transplant Proc 2006; 38: 1379.
481. Prieto Castro RM, Anglada Curado FJ, Regueiro Lopez JC et al: Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction. BJU Int 2001; 88: 241.
482. Russo D, Musone D, Alteri V et al: Erectile dysfunction in kidney transplanted patients: efficacy of sildenafil. J Nephrol 2004; 17: 291.
483. Sharma RK, Prasad N, Gupta A et al: Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial. Am J Kidney Dis 2006; 48: 128.
484. Zhang Y, Guan DL, Ou TW et al: Sildenafil citrate treatment for erectile dysfunction after kidney transplantation. Transplant Proc 2005; 37: 2100.
485. Derry FA, Dinsmore WW, Fraser M et al: Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998; 51: 1629.
486. Ergin S, Gunduz B, Ugurlu H et al: A placebo-controlled, multicenter, randomized, double-blind, flexible-dose, two-way crossover study to evaluate the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction. J Spinal Cord Med 2008; 31: 522.
487. Gans WH, Zaslau S, Wheeler S et al: Efficacy and safety of oral sildenafil in men with erectile dysfunction and spinal cord injury. J Spinal Cord Med 2001; 24: 35.
488. Giuliano F, Hultling C, El Mashy WS et al: Sildenafil citrate (Viagra®): a novel oral treatment for erectile dysfunction caused by traumatic spinal cord injury. Int J Clin Pract Suppl. 1999; 102: 30.
489. Giuliano F, Rubio-Aurioles E, Kennelly M et al: Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006; 66: 210.
490. Giuliano F, Sanchez-Ramos A, Lochner-Ernst D et al: Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury. Arch Neurol 2007; 64: 1584.
491. Khorrami MH, Javid A, Moshtaghi D et al: Sildenafil efficacy in erectile dysfunction secondary to spinal cord injury depends on the level of cord injuries. Int J Androl 2010; 33: 861.
492. Kimoto Y, Sakamoto S, Fujikawa K et al: Up-titration of vardena fi l dose from 10 mg to 20 mg improved erectile function in men with spinal cord injury. Int J Urol 2006; 13: 1428.
493. Lombardi G, Macchiarella A, Cecconi F et al: Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. J Sex Med 2009; 6: 1248.
494. Manou BK, van Tam PN, Sesay M et al: Effect of sildenafil on erectile dysfunction in spinal cord injured patients. Ghana Med J 2009; 43: 132.
495. Maytom MC, Derry FA, Dinsmore WW et al: A two-part pilot study of sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Spinal Cord 1999; 37: 110.
496. Moemen MN, Fahmy I, AbdelAal M et al: Erectile dysfunction in spinal cord-injured men: different treatment options. Int J Impot Res 2008; 20: 181.
497. Sanchez Ramos A, Vidal J, Jauregui ML et al: Efficacy, safety and predictive factors of therapeutic success with sildenafil for erectile dysfunction in patients with different spinal cord injuries. Spinal Cord 2001; 39: 637.
498. Soler JM, Previnaire JG, Denys P et al: Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men. Spinal Cord 2007; 45: 169.
499. Tuzgen S, Karamehmetoglu SS, Karacan I et al: Use of sildenafil in the treatment of erectile dysfunction in patients with spinal cord injury. Neurosurgery Quarterly 2006; 16: 40.
500. Miller NR and Arnold AC: Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy. Eye (Lond) 2015; 29: 65.
501. Lee MS, Grossman D, Arnold AC et al: Incidence of nonarteritic anterior ischemic optic neuropathy: increased risk among diabetic patients. Ophthalmology 2011; 118: 959.
502. Zotz RB, Finger C, Scharf RE et al: Associations between thrombophilic risk factors and determinants of atherosclerosis and inflammation in patients with non-arteritic anterior ischaemic optic neuropathy. Hamostaseologie 2016; 36: 46.
503. Campbell UB, Walker AM, Gaffney M et al: Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. J Sex Med 2015; 12: 139.
504. Margo CE and French DD: Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors. Am J Ophthalmol 2007; 143: 538.
505. Flahavan EM, Li H, Gupte-Singh K et al: Prospective case-crossover study investigating the possible association between nonarteritic anterior ischemic optic neuropathy and phosphodiesterase type 5 inhibitor exposure. Urology 2017; 105: 76.
506. Pomeranz HD: The relationship between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 2016; 36: 193.
507. Li WQ, Qureshi AA, Robinson KC et al: Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med 2014; 174: 964.
508. Loeb S, Folkvaljon Y, Lambe M et al: Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 2015; 313: 2449.
509. Lian Y, Yin H, Pollak MN et al: Phosphodiesterase type 5 inhibitors and the risk of melanoma skin cancer. Eur Urol 2016; 70: 808.
510. Pottegard A, Schmidt SA, Olesen AB et al: Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma. Br J Cancer 2016; 115: 895.
511. Matthews A, Langan SM, Douglas IJ et al: Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK clinical practice research datalink. PLoS Med 2016; 13: e1002037.
512. Hill AB: The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295.
513. Michl U, Molfenter F, Graefen M et al: Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy. J Urol 2015; 193: 479.
514. Gallina A, Bianchi M, Gandaglia G et al: A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy. Eur Urol 2015; 68: 750.
515. Loeb S, Folkvaljon Y, Robinson D et al: Phosphodiesterase type 5 inhibitor use and disease recurrence after prostate cancer treatment. Eur Urol 2016; 70: 824.
516. Jamnagerwalla J, Howard LE, Vidal AC et al: The association between phosphodiesterase type 5 inhibitors and prostate cancer: results from the REDUCE study. J Urol 2016; 196: 715.
517. Atiemo HO, Szostak MJ and Sklar GN: Salvage of sildenafil failures referred from primary care physicians. J Urol 2003; 170: 2356.
518. Jiann BP, Yu CC, Su CC et al: Rechallenge prior sildenafil nonresponders. Int J Impot Res 2004; 16: 64.
519. Hatzichristou D, Moysidis K, Apostolidis A et al: Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol 2005; 47: 518.
520. Gruenwald I, Shenfeld O, Chen J et al: Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 2006; 50: 134.
521. Kim ED, Seftel AD, Goldfischer ER et al: A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. J Sex Med 2013; 11: 820.
522. Carson CC, Hatzichristou DG, Carrier S et al: Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2004; 94: 1301.
523. Brisson TE, Broderick GA, Thiel DD et al: Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction. Urology 2006; 68: 397.
524. Ozgur BC, Gonenc F and Yazicioglu AH: Sildenafil or vardenafil nonresponders' erectile response to tadalafil. Urol J 2009; 6: 267.
525. Wespes E, Rammal A and Garbar C: Sildenafil non-responders: haemodynamic and morphometric studies. Eur Urol 2005; 48: 136.
526. Salonia A, Adaikan G, Buvat J et al: Sexual rehabilitation after treatment for prostate cancer-part 2: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med 2017; 14: 297.
527. Salonia A, Adaikan G, Buvat J et al: Sexual rehabilitation after treatment for prostate cancer-part 1: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). J Sex Med 2017; 14: 285.
528. Sopko NA and Burnett AL: Erection rehabilitation following prostatectomy - current strategies and future directions. Nat Rev Urol 2016; 13: 216.
529. Basal S, Wambi C, Acikel C et al: Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function. BJU Int 2013; 111: 658.
530. Fode M, Serefoglu EC, Albersen M et al: Sexuality following radical prostatectomy: is restoration of erectile function enough? Sex Med Rev 2017; 5: 110.
531. Walz J, Epstein JI, Ganzer R et al: A critical analysis of the current knowledge of surgical anatomy of the prostate related to optimisation of cancer control and preservation of continence and erection in candidates for radical prostatectomy: an update. Eur Urol 2016; 70: 301.
532. Nguyen LN, Head L, Witiuk K et al: The risks and benefits of cavernous neurovascular bundle sparing during radical prostatectomy: a systematic review and meta-analysis. J Urol 2017; 198: 760.
533. Schover LR, Fouladi RT, Warneke CL et al: The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 2002; 95: 2397.
534. Donovan KA, Walker LM, Wassersug RJ et al: Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer 2015; 121: 4286.
535. Nelson CJ and Kenowitz J: Communication and intimacy-enhancing interventions for men diagnosed with prostate cancer and their partners. J Sex Med 2013; 10 Suppl 1: 127.
536. Tal R, Alphs HH, Krebs P et al: Erectile function recovery rate after radical prostatectomy: a meta-analysis. J Sex Med 2009; 6: 2538.
537. al-Abany M, Steineck G, Agren Cronqvist AK et al: Improving the preservation of erectile function after external beam radiation therapy for prostate cancer. Radiother Oncol 2000; 57: 201.
538. van der Wielen GJ, van Putten WL and Incrocci L: Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys 2007; 68: 479.
539. Burnett AL, Aus G, Canby-Hagino ED et al: Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 2007; 178: 597.
540. Ficarra V, Novara G, Ahlering TE et al: Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012; 62: 418.
541. Rabbani F, Schiff J, Piecuch M et al: Time course of recovery of erectile function after radical retropubic prostatectomy: does anyone recover after 2 years? J Sex Med 2010; 7: 3984.
542. Nelson CJ, Scardino PT, Eastham JA et al: Back to baseline: erectile function recovery after radical prostatectomy from the patients' perspective. J Sex Med 2013; 10: 1636.
543. Litwin MS, Flanders SC, Pasta DJ et al: Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999; 54: 503.
544. Mahmood J, Shamah AA, Creed TM et al: Radiation-induced erectile dysfunction: recent advances and future directions. Adv Radiat Oncol 2016; 1: 161.
545. Mulhall JP, Bella AJ, Briganti A et al: Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med 2010; 7: 1687.
546. Burnett AL and Lue TF: Neuromodulatory therapy to improve erectile function recovery outcomes after pelvic surgery. J Urol 2006; 176: 882.
547. Weyne E, Castiglione F, Van der Aa F et al: Landmarks in erectile function recovery after radical prostatectomy. Nat Rev Urol 2015; 12: 289.
548. Ryu JK, Suh JK and Burnett AL: Research in pharmacotherapy for erectile dysfunction. Transl Androl Urol 2017; 6: 207.
549. Segal RL, Bivalacqua TJ and Burnett AL: Current penile-rehabilitation strategies: clinical evidence. Arab J Urol 2013; 11: 230.
550. Sadovsky R, Basson R, Krychman M et al: Cancer and sexual problems. J Sex Med 2010; 7: 349.
551. Walker LM, Wassersug RJ and Robinson JW: Psychosocial perspectives on sexual recovery after prostate cancer treatment. Nat Rev Urol 2015; 12: 167.
552. Salonia A, Burnett AL, Graefen M et al: Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and org*smic function. Eur Urol 2012; 62: 273.
553. Aversa A, Isidori AM, Spera G et al: Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003; 58: 632.
554. Buvat J, Montorsi F, Maggi M et al: Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011; 8: 284.
555. Shabsigh R, Kaufman JM, Steidle C et al: Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658.
556. Spitzer M, Basaria S, Travison TG et al: Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med 2012; 157: 681.
557. Shamloul R, Ghanem H, Fahmy I et al: Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med 2005; 2: 559.
558. Kalinchenko SY, Kozlov GI, Gontcharov NP et al: Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003; 6: 94.
559. Rosenthal BD, May NR, Metro MJ et al: Adjunctive use of Androgel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006; 67: 571.
560. Yassin AA, Saad F and Diede HE: Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia 2006; 38: 61. 561. Hwang TI, Chen HE, Tsai TF et al: Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res 2006; 18: 400.
562. Kim JW, Oh MM, Park MG et al: Combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-reponders with severe and intermediate testosterone deficiency. Int J Impot Res 2013; 25: 29.
563. Alhathal N, Elshal AM and Carrier S: Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: a systematic review. Can Urol Assoc J 2012; 6: 269.
564. Corona G, Isidori AM, Buvat J et al: Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 2014; 11: 1577.
565. Bolona ER, Uraga MV, Haddad RM et al: Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82: 20.
566. Huo S, Scialli AR, McGarvey S et al: Treatment of men for "low testosterone:" a systematic review. PLoS One 2016; 11: e0162480.
567. Algeffari M, Jayasena CN, MacKeith P et al: Testosterone therapy for sexual dysfunction in men with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Med 2018; 35: 195.
568. al-Juburi AZ and O'Donnell PD: Synergist erection system: clinical experience. Urology 1990; 35: 304.
569. Aloui R, Iwaz J, Kokkidis MJ et al: A new vacuum device as alternative treatment for impotence. Br J Urol 1992; 70: 652.
570. Asopa R and Williams G: Use of the "correctaid" device in the management of impotence. Br J Urol 1989; 63: 546.
571. Baltaci S, Aydos K, Kosar A et al: Treating erectile dysfunction with a vacuum tumescence device: a retrospective analysis of acceptance and satisfaction. Br J Urol 1995; 76: 757.
572. Blackard CE, Borkon WD, Lima JS et al: Use of vacuum tumescence device for impotence secondary to venous leakage. Urology 1993; 41: 225.
573. Bosshardt RJ, Farwerk R, Sikora R et al: Objective measurement of the effectiveness, therapeutic success and dynamic mechanisms of the vacuum device. Br J Urol 1995; 75: 786.
574. Broderick GA, Allen G and McClure RD: Vacuum tumescence devices: the role of papaverine in the selection of patients. J Urol 1991; 145: 284.
575. Cookson MS and Nadig PW: Long-term results with vacuum constriction device. J Urol 1993; 149: 290.
576. Derouet H, Caspari D, Rohde V et al: Treatment of erectile dysfunction with external vacuum devices. Andrologia 1999; 31 Suppl 1: 89.
577. Dutta TC and Eid JF: Vacuum constriction devices for erectile dysfunction: a long-term, prospective study of patients with mild, moderate, and severe dysfunction. Urology 1999; 54: 891.
578. Earle CM, Seah M, Coulden SE et al: The use of the vacuum erection device in the management of erectile impotence. Int J Impot Res 1996; 8: 237.
579. el-Bahrawy M, el-Baz MA, Emam A et al: Noninvasive vacuum constriction device in the management of erectile dysfunction. Int Urol Nephrol 1995; 27: 331.
580. Gilbert HW and Gingell JC: Vacuum constriction devices: second-line conservative treatment for impotence. Br J Urol 1992; 70: 81. 581. Gould JE, Switters DM, Broderick GA et al: External vacuum devices: a clinical comparison with pharmacologic erections. World J Urol 1992; 10: 68.
582. Kaplan FJ, Levitt NS, Stevens PJ et al: Non-invasive management of organic impotence. S Afr Med J 1995; 85: 276.
583. Khayyamfar F, Forootan SK, Ghasemi H et al: Evaluating the efficacy of vacuum constrictive device and causes of its failure in impotent patients. Urol J 2013; 10: 1072.
584. Kolettis PN, Lakin MM, Montague DK et al: Efficacy of the vacuum constriction device in patients with corporeal venous occlusive dysfunction. Urology 1995; 46: 856.
585. Korenman SG and Viosca SP: Use of a vacuum tumescence device in the management of impotence in men with a history of penile implant or severe pelvic disease. J Am Geriatr Soc 1992; 40: 61.
586. Korenman SG, Viosca SP, Kaiser FE et al: Use of a vacuum tumescence device in the management of impotence. J Am Geriatr Soc 1990; 38: 217.
587. Lewis RW and Witherington R: External vacuum therapy for erectile dysfunction: use and results. World J Urol 1997; 15: 78.
588. Meinhardt W, Lycklama a Nijeholt AA, Kropman RF et al: The negative pressure device for erectile disorders: when does it fail? J Urol 1993; 149: 1285.
589. Moul JW and McLeod DG: Negative pressure devices in the explanted penile prosthesis population. J Urol 1989; 142: 729.
590. Nadig PW, Ware JC and Blumoff R: Noninvasive device to produce and maintain an erection-like state. Urology 1986; 27: 126.
591. Opsomer RJ, Wese FX, De Groote P et al: The external vacuum device in the management of erectile dysfunction. Acta Urol Belg 1997; 65: 13.
592. Segenreich E, Israilov SR, Shmueli J et al: Vacuum therapy combined with psychotherapy for management of severe erectile dysfunction. Eur Urol 1995; 28: 47.
593. Sidi AA, Becher EF, Zhang G et al: Patient acceptance of and satisfaction with an external negative pressure device for impotence. J Urol 1990; 144: 1154.
594. Sidi AA and Lewis JH: Clinical trial of a simplified vacuum erection device for impotence treatment. Urology 1992; 39: 526.
595. Turner LA, Althof SE, Levine SB et al: External vacuum devices in the treatment of erectile dysfunction: a one-year study of sexual and psychosocial impact. J Sex Marital Ther 1991; 17: 81.
596. Turner LA, Althof SE, Levine SB et al: Treating erectile dysfunction with external vacuum devices: impact upon sexual, psychological and marital functioning. J Urol 1990; 144: 79.
597. van Thillo EL and Delaere KP: The vacuum erection device. A noninvasive treatment for impotence. Acta Urol Belg 1992; 60: 9.
598. Villeneuve R, Corcos J and Carmel M: Assisted erection follow-up with couples. J Sex Marital Ther 1991; 17: 94.
599. Vrijhof HJ and Delaere KP: Vacuum constriction devices in erectile dysfunction: acceptance and effectiveness in patients with impotence of organic or mixed aetiology. Br J Urol 1994; 74: 102.
600. Willard BA: An assessment of a vacuum constriction device in treating erectile dysfunction. Urol Nurs 1998; 18: 33.
601. Witherington R: Vacuum constriction device for management of erectile impotence. J Urol 1989; 141: 320.
602. Arauz-Pacheco C, Basco M, Ramirez LC et al: Treatment of diabetic impotence with a vacuum device: efficacy and effects on psychological status. Am J Med Sci 1992; 303: 281.
603. Bodansky HJ: Treatment of male erectile dysfunction using the active vacuum assist device. Diabet Med 1994; 11: 410.
604. Famuyiwa OO, Al-Jasser SJ, Ahmad AS et al: Experience with the vacuum-enhanced tumescence erecaid system in the treatment of erectile impotence among diabetic patients in Saudi Arabia. Practical Diabetes 1992; 9: 141.
605. Israilov S, Shmuely J, Niv E et al: Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2005; 17: 431.
606. Pajovic B, Dimitrovski A, Fatic N et al: Vacuum erection device in treatment of organic erectile dysfunction and penile vascular differences between patients with DM type I and DM type II. Aging Male 2017; 20: 49.
607. Price DE, Cooksey G, Jehu D et al: The management of impotence in diabetic men by vacuum tumescence therapy. Diabet Med 1991; 8: 964.
608. Sun L, Peng FL, Yu ZL et al: Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. Int J Urol 2014; 21: 1263.
609. Engel JD: Effect on sexual function of a vacuum erection device post-prostatectomy. Can J Urol 2011; 18: 5721.
610. Nason GJ, McNamara F, Twyford M et al: Efficacy of vacuum erectile devices (VEDs) after radical prostatectomy: the initial Irish experience of a dedicated VED clinic. Int J Impot Res 2016; 6: 205.
611. Raina R, Agarwal A, Ausmundson S et al: Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 2006; 18: 77.
612. Denil J, Ohl DA and Smythe C: Vacuum erection device in spinal cord injured men: patient and partner satisfaction. Arch Phys Med Rehabil 1996; 77: 750.
613. Heller L, Aloni R, Keren O et al: Vacuum tumescence constriction therapy for neuropathic impotence. Int J Adolesc Med Health 1994; 7: 255.
614. Lloyd EE, Toth LL and Perkash I: Vacuum tumescence: an option for spinal cord injured males with erectile dysfunction. SCI Nurs 1989; 6: 25. 615. Seckin B, Atmaca I, Ozgok Y et al: External vacuum device therapy for spinal cord injured males with erectile dysfunction. Int Urol Nephrol 1996; 28: 235.
616. Watanabe T, Chancellor MB, Rivas DA et al: Epidemiology of current treatment for sexual dysfunction in spinal cord injured men in the USA model spinal cord injury centers. J Spinal Cord Med 1996; 19: 186.
617. Zasler ND and Katz PG: Synergist erection system in the management of impotence secondary to spinal cord injury. Arch Phys Med Rehabil 1989; 70: 712.
618. Chen J, Mabjeesh NJ and Greenstein A: Sildenafil versus the vacuum erection device: patient preference. J Urol 2001; 166: 1779.
619. Canguven O, Bailen J, Fredriksson W et al: Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. J Sex Med 2009; 6: 2561.
620. Kohler TS, Pedro R, Hendlin K et al: A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int 2007; 100: 858.
621. Brison D, Seftel A and Sadeghi-Nejad H: The resurgence of the vacuum erection device (VED) for treatment of erectile dysfunction. J Sex Med 2013; 10: 1124.
622. Padma-Nathan H, Hellstrom WJ, Kaiser FE et al: Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997; 336: 1.
623. Williams G, Abbou CC, Amar ET et al: Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br J Urol 1998; 81: 889.
624. Shokeir AA, Alserafi MA and Mutabagani H: Intracavernosal versus intraurethral alprostadil: a prospective randomized study. BJU Int 1999; 83: 812.
625. Shabsigh R, Padma-Nathan H, Gittleman M et al: Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology 2000; 55: 109.
626. Chiang HS, Wen TC and Liang JF: Titration study of MUSE (Medicated Urethral System for Erection) in erectile dysfunction. J Formos Med Assoc 2000; 99: 926.
627. Ekman P, Sjogren L, Englund G et al: Optimizing the therapeutic approach of transurethral alprostadil. BJU Int 2000; 86: 68.
628. Guay AT, Perez JB, Velasquez E et al: Clinical experience with intraurethral alprostadil (MUSE) in the treatment of men with erectile dysfunction. A retrospective study. Medicated urethral system for erection. Eur Urol 2000; 38: 671.
629. Jaffe JS, Antell MR, Greenstein M et al: Use of intraurethral alprostadil in patients not responding to sildenafil citrate. Urology 2004; 63: 951.
630. Khan MA, Raistrick M, Mikhailidis DP et al: MUSE: clinical experience. Curr Med Res Opin 2002; 18: 64.
631. Kim SC, Ahn TY, Choi HK et al: Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea. Int J Impot Res 2000; 12: 97.
632. Kongkanand A, Ratana-Olarn K, Wuddhikarn S et al: Evaluation of transurethal alprostadil for safety and efficacy in men with erectile dysfunction. J Med Assoc Thai 2002; 85: 223.
633. Mulhall JP, Jahoda AE, Ahmed A et al: Analysis of the consistency of intraurethral prostaglandin E1 (MUSE) during at-home use. Urology 2001; 58: 262.
634. Garrido Abad P, Sinues Ojas B, Martinez Blazquez L et al: Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors. Actas Urol Esp 2015; 39: 635.
635. Pangkahila WI: Evaluation of transurethral application of alprostadil for erectile dysfunction in Indonesians. Asian J Androl 2000; 2: 233.
636. Shabsigh R, Padma-Nathan H, Gittleman M et al: Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000; 55: 477.
637. Hatzichristou DG, Apostolidis A, Tzortzis V et al: Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol 2000; 164: 1197.
638. al-Juburi AZ and O'Donnell PD: Follow up outcome of intracavernous papaverine. J Ark Med Soc 1990; 86: 383.
639. Alexandre B, Lemaire A, Desvaux P et al: Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment. J Sex Med 2007; 4: 426.
640. Althof SE, Turner LA, Levine SB et al: Intracavernosal injection in the treatment of impotence: a prospective study of sexual, psychological, and marital functioning. J Sex Marital Ther 1987; 13: 155.
641. Althof SE, Turner LA, Levine SB et al: Sexual, psychological, and marital impact of self-injection of papaverine and phentolamine: a long-term prospective study. J Sex Marital Ther 1991; 17: 101.
642. Armstrong DK, Convery A and Dinsmore WW: Intracavernosal papaverine and phentolamine for the medical management of erectile dysfunction in a genitourinary clinic. Int J STD AIDS 1993; 4: 214.
643. Armstrong DK, Convery A and Dinsmore WW: Prostaglandin E1 in the medical management of erectile dysfunction in a genito-urinary medicine clinic. Ulster Med J 1994; 63: 18.
644. Armstrong DK, Convery AG and Dinsmore WW: Reasons for patient drop-out from an intracavernous auto-injection programme for erectile dysfunction. Br J Urol 1994; 74: 99.
645. Bahren W, Scherb W, Gall H et al: Effects of intracavernosal pharmacotherapy on self-esteem, performance anxiety and partnership in patients with chronic erectile dysfunction. Eur Urol 1989; 16: 175.
646. Baniel J, Israilov S, Engelstein D et al: Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs. Urology 2000; 56: 647.
647. Baum N, Randrup E, Junot D et al: Prostaglandin E1 versus sex therapy in the management of psychogenic erectile dysfunction. Int J Impot Res 2000; 12: 191.
648. Bennett AH, Carpenter AJ and Barada JH: An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991; 146: 1564.
649. Beretta G, Zanollo A, Ascani L et al: Prostaglandin E1 in the therapy of erectile deficiency. Acta Eur Fertil 1989; 20: 305.
650. Brindley GS: Maintenance treatment of erectile impotence by cavernosal unstriated muscle relaxant injection. Br J Psychiatry 1986; 149: 210.
651. Brock G, Tu LM and Linet OI: Return of spontaneous erection during long-term intracavernosal alprostadil (CAVERJECT) treatment. Urology 2001; 57: 536.
652. Brown SL, Haas CA, Koehler M et al: Hepatotoxicity related to intracavernous pharmacotherapy with papaverine. Urology 1998; 52: 844.
653. Buvat J, Costa P, Morlier D et al: Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol 1998; 159: 116.
654. Buvat J, Lemaire A and Herbaut-Buvat M: Intracavernous pharmacotherapy: comparison of moxisylyte and prostaglandin E1. Int J Impot Res 1996; 8: 41.
655. Canale D, Giorgi PM, Lencioni R et al: Long-term intracavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction. Int J Androl 1996; 19: 28.
656. Casabe A, Bechara A, Cheliz G et al: Drop-out reasons and complications in self-injection therapy with a triple vasoactive drug mixture in sexual erectile dysfunction. Int J Impot Res 1998; 10: 5.
657. Chen J, Godschalk M, Katz PG et al: The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction. J Urol 1995; 153: 80.
658. Chen J, Godschalk MF, Katz PG et al: Incidence of penile pain after injection of a new formulation of prostaglandin E1. J Urol 1995; 154: 77.
659. Chen RN, Lakin MM, Montague DK et al: Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis. J Urol 1996; 155: 138.
660. Chew KK, Stuckey BG, Earle CM et al: Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction. Int J Impot Res 1997; 9: 225.
661. Chiang HS, Wen TC, Wu CC et al: Intracavernous self-injection therapy for the treatment of erectile dysfunction. J Formos Med Assoc 1992; 91: 898.
662. Coombs PG, Heck M, Guhring P et al: A review of outcomes of an intracavernosal injection therapy programme. BJU Int 2012; 110: 1787.
663. Cooper AJ: Evaluation of I-C papaverine in patients with psychogenic and organic impotence. Can J Psychiatry 1991; 36: 574.
664. de la Taille A, Delmas V, Amar E et al: Reasons of dropout from short- and long-term self-injection therapy for impotence. Eur Urol 1999; 35: 312.
665. Dhabuwala CB, Kerkar P, Bhutwala A et al: Intracavernous papaverine in the management of psychogenic impotence. Arch Androl 1990; 24: 185.
666. Dinsmore WW: Medical treatment of impotence with papaverine and phentolamine intracavernosal injection. Ulster Med J 1990; 59: 174.
667. Dinsmore WW, Gingell C, Hackett G et al: Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. BJU Int 1999; 83: 274.
668. El-Sakka AI: Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction. Int J Impot Res 2006; 18: 180.
669. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group. Br J Urol 1998; 82: 538.
670. Flynn RJ and Williams G: Long-term follow-up of patients with erectile dysfunction commenced on self injection with intracavernosal papaverine with or without phentolamine. Br J Urol 1996; 78: 628.
671. Gall H, Sparwasser C, Bahren W et al: Long-term results of corpus cavernosum autoinjection therapy for chronic erectile dysfunction. Andrologia 1992; 24: 285.
672. Gerber GS and Levine LA: Pharmacological erection program using prostaglandin E1. J Urol 1991; 146: 786.
673. Gerstenberg TC, Metz P, Ottesen B et al: Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 1992; 147: 1277.
674. Girdley FM, Bruskewitz RC, Feyzi J et al: Intracavernous self-injection for impotence: a long-term therapeutic option? Experience in 78 patients. J Urol 1988; 140: 972.
675. Godschalk M, Gheorghiu D, Chen J et al: Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure. J Urol 1996; 155: 915.
676. Godschalk MF, Chen J, Katz PG et al: Prostaglandin E1 as treatment for erectile failure in elderly men. J Am Geriatr Soc 1994; 42: 1263.
677. Godschalk MF, Chen J, Katz PG et al: Treatment of erectile failure with prostaglandin E1: a double-blind, placebo-controlled, dose-response study. J Urol 1994; 151: 1530.
678. Govier FE, McClure RD, Weissman RM et al: Experience with triple-drug therapy in a pharmacological erection program. J Urol 1993; 150: 1822.
679. Gupta R, Kirschen J, Barrow RC et al: Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol 1997; 157: 1681.
680. Hattat H, Ozkara H, Akkus E et al: Our experience with pharmacological erection treatment of erectile dysfunction. J Androl 1994; 15 Suppl: 47s.
681. Hauck EW, Altinkilic BM, Schroeder-Printzen I et al: Prostaglandin E1 long-term self-injection programme for treatment of erectile dysfunction--a follow-up of at least 5 years. Andrologia 1999; 31 Suppl 1: 99.
682. He L, Wen J, Jiang X et al: Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China. Andrologia 2011; 43: 208.
683. Hirsch IH, Schanne FJ, Carsello J et al: Sequential penile ultrasound monitoring of patients treated with chronic intracavernous prostaglandin E1. Urology 1995; 45: 1037.
684. Hollander JB, Gonzalez J and Norman T: Patient satisfaction with pharmacologic erection program. Urology 1992; 39: 439.
685. Hsiao W, Bennett N, Guhring P et al: Satisfaction profiles in men using intracavernosal injection therapy. J Sex Med 2011; 8: 512.
686. Irwin MB and Kata EJ: High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology 1994; 43: 84.
687. Ismail M, Abbott L and Hirsch IH: Experience with intracavernous PGE-1 in the treatment of erectile dysfunction: dose considerations and efficacy. Int J Impot Res 1997; 9: 39.
688. Janosko EO: Intracavernous self-injection of papaverine and regitine for the treatment of organic impotence. N C Med J 1986; 47: 305.
689. Kaplan SA, Reis RB, Kohn IJ et al: Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. Urology 1998; 52: 739.
690. Kerfoot WW and Carson CC: Pharmacologically induced erections among geriatric men. J Urol 1991; 146: 1022.
691. Khan MM and Khwaja M: Open label study of intracavernous injection of alpostadil alphadex in the treatment of erectile dysfunction. Journal of Postgraduate Medical Institute 2005; 19: 52.
692. Kirkeby HJ and Johannesen NL: Pharmacologically induced prolonged erections produced by papaverine. Follow-up of injection therapy. Scand J Urol Nephrol Suppl 1989; 125: 97.
693. Kunelius P and Lukkarinen O: Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction. Int J Impot Res 1999; 11: 21.
694. Lakin MM, Montague DK, VanderBrug Medendorp S et al: Intracavernous injection therapy: analysis of results and complications. J Urol 1990; 143: 1138.
695. Lehmann K, Casella R, Blochlinger A et al: Reasons for discontinuing intracavernous injection therapy with prostaglandin E1 (alprostadil). Urology 1999; 53: 397.
696. Levine SB, Althof SE, Turner LA et al: Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989; 141: 54.
697. Linet OI and Ogrinc FG: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996; 334: 873.
698. Willke RJ, Glick HA, McCarron TJ et al: Quality of life effects of alprostadil therapy for erectile dysfunction. J Urol 1997; 157: 2124.
699. Lloyd LK and Richards JS: Intracavernous pharmacotherapy for management of erectile dysfunction in spinal cord injury. Paraplegia 1989; 27: 457.
700. Lundberg L, Olsson JO and Kihl B: Long-term experience of self-injection therapy with prostaglandin E1 for erectile dysfunction. Scand J Urol Nephrol 1996; 30: 395.
701. Meinhardt W, de la Fuente RB, Lycklama a Nijeholt AA et al: Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction. Int J Impot Res 1996; 8: 5.
702. Meinhardt W, Lycklama a Nijeholt AA, Kropman RF et al: Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections. Eur Urol 1994; 26: 319.
703. Moemen MN, Hamed HA, Kamel, II et al: Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances. Int J Impot Res 2004; 16: 143.
704. Montorsi F, Guazzoni G, Bergamaschi F et al: Effectiveness and safety of multidrug intracavernous therapy for vasculogenic impotence. Urology 1993; 42: 554.
705. Montorsi F, Guazzoni G, Bergamaschi F et al: Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction. J Urol 1993; 149: 1291.
706. Mulhall JP, Jahoda AE, Cairney M et al: The causes of patient dropout from penile self-injection therapy for impotence. J Urol 1999; 162: 1291.
707. Nellans RE, Ellis LR and Kramer-Levien D: Pharmacological erection: diagnosis and treatment applications in 69 patients. J Urol 1987; 138: 52.
708. Nelson RP: Injections of papaverine and regitine into the corpora cavernosa for erectile dysfunction: clinical results in 60 patients. South Med J 1989; 82: 26.
709. Nisen H: Cavernous auto-injection therapy with prostaglandin E1. Ann Chir Gynaecol Suppl 1993; 206: 69.
710. Pagliarulo A, Ludovico GM, Cirillo-Marucco E et al: Compliance to longterm vasoactive intracavernous therapy. Int J Impot Res 1996; 8: 63.
711. Perimenis P, Athanasopoulos A, Geramoutsos I et al: The incidence of pharmacologically induced priapism in the diagnostic and therapeutic management of 685 men with erectile dysfunction. Urol Int 2001; 66: 27.
712. Perimenis P, Gyftopoulos K, Athanasopoulos A et al: Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs. Eur Urol 2001; 40: 398.
713. Pery M, Rosenberger A, Kaftori JK et al: Intracorporeal calcifications after self-injection of papaverine. Radiology 1990; 176: 81.
714. Porst H, Buvat J, Meuleman E et al: Intracavernous alprostadil alfadex--an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res 1998; 10: 225.
715. Porst H, van Ahlen H, Block T et al: Intracavernous self-injection of prostaglandin E1 in the therapy of erectile dysfunction. Vasa Suppl 1989; 28: 50.
716. Puppo P, De Rose AF, Pittaluga P et al: Diagnosis of male impotence after intracavernous papaverine test. Eur Urol 1988; 15: 213.
717. Purvis K, Egdetveit I and Christiansen E: Intracavernosal therapy for erectile failure--impact of treatment and reasons for drop-out and dissatisfaction. Int J Impot Res 1999; 11: 287.
718. Rabbani KJ, Tauqeer F and Rabbani R: Prostaglandin E1 for the medical management of erectile dysfunction. Pak J Med Health Sci 2010; 4: 512.
719. Robinette MA and Moffat MJ: Intracorporal injection of papaverine and phentolamine in the management of impotence. Br J Urol 1986; 58: 692.
720. Robinson PK: An observational study of prostaglandin E1: comparing trial and maintenance dose. Urol Nurs 1994; 14: 76.
721. Rowland DL, Boedhoe HS, Dohle G et al: Intracavernosal self-injection therapy in men with erectile dysfunction: satisfaction and attrition in 119 patients. Int J Impot Res 1999; 11: 145.
722. Ruutu M, Lindstrom BL, Virtanen J et al: Intracavernous self-injection for erectile failure. Eur Urol 1988; 15: 96.
723. Sandhu D, Curless E, Dean J et al: A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res 1999; 11: 91.
724. Schramek P, Dorninger R, Waldhauser M et al: Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism. Br J Urol 1990; 65: 68.
725. Sexton WJ, Benedict JF and Jarow JP: Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy. J Urol 1998; 159: 811.
726. Shah PJ, Dinsmore W, Oakes RA et al: Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. Curr Med Res Opin 2007; 23: 2577.
727. Sidi AA, Reddy PK and Chen KK: Patient acceptance of and satisfaction with vasoactive intracavernous pharmacotherapy for impotence. J Urol 1988; 140: 293.
728. Soderdahl DW, Thrasher JB and Hansberry KL: Intracavernosal drug-induced erection therapy versus external vacuum devices in the treatment of erectile dysfunction. Br J Urol 1997; 79: 952.
729. Sparwasser C, Drescher P, Pust RA et al: Long-term results of therapy with intracavernousal injections and penile venous surgery in chronic erectile dysfunction. Scand J Urol Nephrol Suppl 1994; 157: 107.
730. Stackl W, Hasun R and Marberger M: Intracavernous injection of prostaglandin E1 in impotent men. J Urol 1988; 140: 66.
731. Stief CG, Gall H, Scherb W et al: Mid-term results of autoinjection therapy for erectile dysfunction. Urology 1988; 31: 483.
732. Sundaram CP, Thomas W, Pryor LE et al: Long-term follow-up of patients receiving injection therapy for erectile dysfunction. Urology 1997; 49: 932.
733. Sung HH, Ahn JS, Kim JJ et al: The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors. Andrology 2014; 2: 45.
734. Torok A, Szekely J and Gotz F: Papaverine-induced erection. Int Urol Nephrol 1989; 21: 195.
735. Turner LA, Althof SE, Levine SB et al: Twelve-month comparison of two treatments for erectile dysfunction: self-injection versus external vacuum devices. Urology 1992; 39: 139.
736. Turner LA, Althof SE, Levine SB et al: Self-injection of papaverine and phentolamine in the treatment of psychogenic impotence. J Sex Marital Ther 1989; 15: 163.
737. Valdevenito R and Melman A: Intracavernous self-injection pharmacotherapy program: analysis of results and complications. Int J Impot Res 1994; 6: 81.
738. van der Windt F, Dohle GR, van der Tak J et al: Intracavernosal injection therapy with and without sexological counselling in men with erectile dysfunction. BJU Int 2002; 89: 901.
739. Virag R, Shoukry K, Floresco J et al: Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol 1991; 145: 287.
740. Watters GR, Keogh EJ, Earle CM et al: Experience in the management of erectile dysfunction using the intracavernosal self-injection of vasoactive drugs. J Urol 1988; 140: 1417.
741. Weidner W, Schroeder-Printzen I, Fischer C et al: Experience in the treatment of erectile dysfunction using the intracavernosal self-injection of papaverine: results of a prospective study after a median follow-up of 42 months involving 135 patients and 10766 injections. World J Urol 1992; 10: 179.
742. Weiss JN, Badlani GH, Ravalli R et al: Reasons for high drop-out rate with self-injection therapy for impotence. Int J Impot Res 1994; 6: 171.
743. Williams G, Mulcahy MJ and Kiely EA: Impotence: treatment by autoinjection of vasoactive drugs. Br Med J (Clin Res Ed) 1987; 295: 595.
744. Wu CC, Xue ZY, Apichat K et al: The use of alprostadil sterile powder in a home self-injection study of Asian men with erectile dysfunction. Clin Ther 1996; 18: 256.
745. Bell DS, Cutter GR, Hayne VB et al: Factors predicting efficacy of phentolamine-papaverine intracorporeal injection for treatment of erectile dysfunction in diabetic male. Urology 1992; 40: 36.
746. Heaton JP, Lording D, Liu SN et al: Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001; 13: 317.
747. Montorsi F, Guazzoni G, Bergamaschi F et al: Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence. Acta Diabetol 1994; 31: 1.
748. Perimenis P, Konstantinopoulos A, Perimeni PP et al: Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl 2006; 8: 219.
749. Tsai YS, Lin JS and Lin YM: Safety and efficacy of alprostadil sterile powder (s. Po., CAVERJECT) in diabetic patients with erectile dysfunction. Eur Urol 2000; 38: 177.
750. Israilov S, Niv E, Livne PM et al: Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. Int J Impot Res 2002; 14: 38.
751. Albaugh JA and Ferrans CE: Impact of penile injections on men with erectile dysfunction after prostatectomy. Urol Nurs 2010; 30: 64.
752. Claro Jde A, de Aboim JE, Maringolo M et al: Intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: an observational study. Sao Paulo Med J 2001; 119: 135.
753. Dennis RL and McDougal WS: Pharmacological treatment of erectile dysfunction after radical prostatectomy. J Urol 1988; 139: 775.
754. Domes T, Chung E, DeYoung L et al: Clinical outcomes of intracavernosal injection in postprostatectomy patients: a single-center experience. Urology 2012; 79: 150.
755. Gontero P, Fontana F, Bagnasacco A et al: Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol 2003; 169: 2166.
756. Montorsi F, Guazzoni G, Strambi LF et al: Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997; 158: 1408.
757. Mydlo JH, Viterbo R and Crispen P: Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU Int 2005; 95: 843.
758. Prabhu V, Alukal JP, Laze J et al: Long-term satisfaction and predictors of use of intracorporeal injections for post-prostatectomy erectile dysfunction. J Urol 2013; 189: 238.
759. Raina R, Lakin MM, Thukral M et al: Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 2003; 15: 318.
760. Yiou R, Bütow Z, Parisot J et al: Is it worth continuing sexual rehabilitation after radical prostatectomy with intracavernous injection of alprostadil for more than 1 year? Sex Med 2015; 3: 42.
761. Yiou R, Cunin P, de la Taille A et al: Sexual rehabilitation and penile pain associated with intracavernous alprostadil after radical prostatectomy. J Sex Med 2011; 8: 575.
762. Mansi MK, Alkhudair WK and Huraib S: Treatment of erectile dysfunction after kidney transplantation with intracavernosal self-injection of prostaglandin E1. J Urol 1998; 159: 1927.
763. Beretta G, Zanollo A, Fanciullacci F et al: Intracavernous injection of papaverine in paraplegic males. Acta Eur Fertil 1986; 17: 283.
764. Bodner DR, Leffler B and Frost F: The role of intracavernous injection of vasoactive medications for the restoration of erection in spinal cord injured males: a three year follow up. Paraplegia 1992; 30: 118.
765. Chao R and Clowers DE: Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction. Arch Phys Med Rehabil 1994; 75: 276.
766. Earle CM, Keogh EJ, Ker JK et al: The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury. Paraplegia 1992; 30: 273.
767. Hirsch IH, Smith RL, Chancellor MB et al: Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction. Paraplegia 1994; 32: 661.
768. Kapoor VK, Chahal AS, Jyoti SP et al: Intracavernous papaverine for impotence in spinal cord injured patients. Paraplegia 1993; 31: 675.
769. Sidi AA, Cameron JS, Dykstra DD et al: Vasoactive intracavernous pharmacotherapy for the treatment of erectile impotence in men with spinal cord injury. J Urol 1987; 138: 539.
770. Tang SF, Chu NK and Wong MK: Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report. Paraplegia 1995; 33: 731.
771. Zaslau S, Nicolis C, Galea G et al: A simplified pharmacologic erection program for patients with spinal cord injury. J Spinal Cord Med 1999; 22: 303.
772. Derouet H, Meeth M and Bewermeier H: Experience with a papaverine/phentolamine/prostaglandin E1-mixture in non-responders to autoinjection therapy. Aktuelle Urologie 1996; 5: 271.
773. Akdemir F, Okulu E and Kayigil O: Long-term outcomes of AMS Spectra® penile prosthesis implantation and satisfaction rates. Int J Impot Res 2017; 5: 184.
774. Casabe AR, Sarotto N, Gutierrez C et al: Satisfaction assessment with malleable prosthetic implant of Spectra (AMS) and Genesis (Coloplast) models. Int J Impot Res 2016; 28: 228.
775. Akin-Olugbade O, Parker M, Guhring P et al: Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med 2006; 3: 743.
776. Al-Najar A, Naumann CM, Kaufmann S et al: Should being aged over 70 years hinder penile prosthesis implantation? BJU Int 2009; 104: 834.
777. Altunkol A, Erçil H, Şener NC et al: Clinical evaluation of outcomes of penile prosthesis implantation and partner satisfaction. Erciyes Tip Dergisi 2014; 36: 148.
778. Anafarta K, Safak M, Beduk Y et al: Clinical experience with inflatable and malleable penile implants in 104 patients. Urol Int 1996; 56: 100.
779. Bae JH, Song PH, Kim HT et al: Assessment of erectile and ejacul*tory function after penile prosthesis implantation. Korean J Urol 2010; 51: 202.
780. Bettocchi C, Palumbo F, Spilotros M et al: Patient and partner satisfaction after AMS inflatable penile prosthesis implant. J Sex Med 2010; 7: 304.
781. Borges F, Hakim L and Kline C: Surgical technique to maintain penile length after insertion of an inflatable penile prosthesis via infrapubic approach. J Sex Med 2006; 3: 550.
782. Bozkurt IH, Arslan B, Kozacioglu Z et al: Does the etiology affect the outcome and satisfaction rates of penile prosthesis implantation surgery? Kaohsiung J Med Sci 2014; 30: 570.
783. Bozkurt IH, Arslan B, Yonguc T et al: Patient and partner outcome of inflatable and semi-rigid penile prosthesis in a single institution. Int Braz J Urol 2015; 41: 535.
784. Brinkman MJ, Henry GD, Wilson SK et al: A survey of patients with inflatable penile prostheses for satisfaction. J Urol 2005; 174: 253.
785. Cakan M, Demirel F, Karabacak O et al: Risk factors for penile prosthetic infection. Int Urol Nephrol 2003; 35: 209.
786. Carson CC, Mulcahy JJ and Govier FE: Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol 2000; 164: 376.
787. Carson CC 3rd, Mulcahy JJ and Harsch MR: Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol 2011; 185: 614.
788. Carvalheira A, Santana R and Pereira NM: Why are men satisfied or dissatisfied with penile implants? A mixed method study on satisfaction with penile prosthesis implantation. J Sex Med 2015; 12: 2474.
789. Chiang HS, Liao CH and Chang ML: Benefits of antibiotic-impregnated inflatable penile prosthesis (InhibiZone®) in patients at high risk of infection in Taiwan. Urological Science 2016; 27: 144.
790. Chiang HS, Wu CC and Wen TC: 10 years of experience with penile prosthesis implantation in Taiwanese patients. J Urol 2000; 163: 476.
791. Chin CM, Jacinto HA and Lim PHC: Penile implant surgery - review of local series. Asian Journal of Surgery 1999; 22: 402.
792. Deuk Choi Y, Jin Choi Y, Hwan Kim J et al: Mechanical reliability of the AMS 700CXM inflatable penile prosthesis for the treatment of male erectile dysfunction. J Urol 2001; 165: 822.
793. Chung E, Solomon M, Deyoung L et al: Clinical outcomes and patient satisfaction rates among elderly male aged ≥75 years with inflatable penile prosthesis implant for medically refractory erectile dysfunction. World J Urol 2013; 1: 173.
794. Chung E, Van CT, Wilson I et al: Penile prosthesis implantation for the treatment for male erectile dysfunction: clinical outcomes and lessons learnt after 955 procedures. World J Urol 2013; 31: 591.
795. Daitch JA, Angermeier KW, Lakin MM et al: Long-term mechanical reliability of AMS 700 series inflatable penile prostheses: Comparison of CX/CXM and Ultrex cylinders. J Urol 1997; 158: 1400.
796. Dhabuwala C, Sheth S and Zamzow B: Infection rates of ifampin/gentamicin-coated Titan Coloplast penile implants. Comparison with Inhibizone-impregnated AMS penile implants. J Sex Med 2011; 8: 315.
797. Dhar NB, Angermeier KW and Montague DK: Long-term mechanical reliability of AMS 700CX/CXM inflatable penile prosthesis. J Urol 2006; 176: 2599.
798. Dorflinger T and Bruskewitz R: AMS malleable penile prosthesis. Urology 1986; 28: 480.
799. Droggin D, Shabsigh R and Anastasiadis AG: Antibiotic coating reduces penile prosthesis infection. J Sex Med 2005; 2: 565.
800. Earle CM, Watters GR, Tulloch AG et al: Complications associated with penile implants used to treat impotence. Aust N Z J Surg 1989; 59: 959.
801. Eid JF, Wilson SK, Cleves M et al: Coated implants and "no touch" surgical technique decreases risk of infection in inflatable penile prosthesis implantation to 0.46%. Urology 2012; 79: 1310.
802. Enemchukwu EA, Kaufman MR, Whittam BM et al: Comparative revision rates of inflatable penile prostheses using woven Dacron® fabric cylinders. J Urol 2013; 190: 2189.
803. Fathy A, Shamloul R, AbdelRahim A et al: Experience with Tube (Promedon) malleable penile implant. Urol Int 2007; 79: 244.
804. Fein RL: GFS Mark II inflatable penile prosthesis: four-year clinical study. Urology 1994; 43: 209.
805. Ferguson KH and Cespedes RD: Prospective long-term results and quality-of-life assessment after DURA-II penile prosthesis placement. Urology 2003; 61: 437.
806. Furlow WL, Goldwasser B and Gundian JC: Implantation of model AMS 700 penile prosthesis: long-term results. J Urol 1988; 139: 741.
807. Knoll LD, Furlow WL and Motley RC: Clinical experience implanting an inflatable penile prosthesis with controlled-expansion cylinder. Urology 1990; 36: 502.
808. Garber BB and Marcus SM: Does surgical approach affect the incidence of inflatable penile prosthesis infection? Urology 1998; 52: 291.
809. Garber BB: Inflatable penile prosthesis: results of 150 cases. Br J Urol 1996; 78: 933.
810. Garber BB: Outpatient inflatable penile prosthesis insertion. Urology 1997; 49: 600. 811. Garber BB: Inflatable penile prosthesis: site-specific malfunction analysis. Int J Impot Res 2003; 15: 22.
812. Gentile G, Franceschelli A, Massenio P et al: Patient's satisfaction after 2-piece inflatable penile prosthesis implantation: an Italian multicentric study. Arch Ital Urol Androl 2016; 88: 1.
813. Goldstein I, Bertero EB, Kaufman JM et al: Early experience with the first pre-connected 3-piece inflatable penile prosthesis: the Mentor Alpha-1. J Urol 1993; 150: 1814.
814. Goldstein I, Newman L, Baum N et al: Safety and efficacy outcome of Mentor Alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol 1997; 157: 833.
815. Grewal S, Vetter J, Brandes SB et al: A population-based analysis of contemporary rates of reoperation for penile prosthesis procedures. Urology 2014; 84: 112.
816. Henry GD, Brinkman MJ, Mead SF et al: A survey of patients with inflatable penile prostheses: assessment of timing and frequency of intercourse and analysis of implant durability. J Sex Med 2012; 9: 1715.
817. Henry GD, Carrion R, Jennermann C et al: Prospective evaluation of postoperative penile rehabilitation: penile length/girth maintenance 1 year following Coloplast Titan inflatable penile prosthesis. J Sex Med 2015; 12: 1298.
818. Hollenbeck BK, Miller DC and Ohl DA: The utility of lockout valve reservoirs in preventing autoinflation in penile prostheses. Int Urol Nephrol 2002; 34: 379.
819. Holloway FB and Farah RN: Intermediate term assessment of the reliability, function and patient satisfaction with the AMS700 Ultrex penile prosthesis. J Urol 1997; 157: 1687.
820. Jarow JP: Risk factors for penile prosthetic infection. J Urol 1996; 156: 402.
821. Jensen JB, Larsen EH, Kirkeby HJ et al: Clinical experience with the Mentor Alpha-1 inflatable penile prosthesis: report on 65 patients. Scand J Urol Nephrol 2005; 39: 69.
822. Jensen JB, Madsen SS, Larsen EH et al: Patient and partner satisfaction with the Mentor Alpha-1 inflatable penile prosthesis. Scand J Urol Nephrol 2005; 39: 66.
823. Ji YS, Ko YH, Song PH et al: Long-term survival and patient satisfaction with inflatable penile prosthesis for the treatment of erectile dysfunction. Korean J Urol 2015; 56: 461.
824. Kilicarslan H, Kaynak Y, Gokcen K et al: Comparison of patient satisfaction rates for the malleable and two piece-inflatable penile prostheses. Turk J Urol 2014; 40: 207.
825. Kim DS, Yang KM, Chung HJ et al: AMS 700CX/CXM inflatable penile prosthesis has high mechanical reliability at long-term follow-up. J Sex Med 2010; 7: 2602.
826. Kucuk EV, Tahra A, Bindayi A et al: Erectile dysfunction patients are more satisfied with penile prosthesis implantation compared with tadalafil and intracavernosal injection treatments. Andrology 2016; 4: 952.
827. Lacy J, Walker J, Gupta S et al: Risk factors for removal or revision of penile prostheses in the veteran population. Urology 2016; 98: 189.
828. Levine LA, Estrada CR and Morgentaler A: Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J Urol 2001; 166: 932.
829. Liberman SN, Gomella LG and Hirsch IH: Experience with the Ultrex and Ultrex Plus inflatable penile prosthesis: new implantation techniques and surgical outcome. Int J Impot Res 1998; 10: 175.
830. Lin AN: Implantation of penile prosthesis: Clinical experience with 105 cases. Asian J Surg 1989; 12: 125.
831. Lindeborg L, Fode M, Fahrenkrug L et al: Satisfaction and complications with the Titan® one-touch release penile implant. Scand J Urol 2014; 48: 105.
832. Lledo-Garcia E, Jara-Rascon J, Moncada Iribarren I et al: Penile prosthesis first and replacement surgeries: analysis of patient and partner satisfaction. J Sex Med 2015; 12: 1646.
833. Lotan Y, Roehrborn CG, McConnell JD et al: Factors influencing the outcomes of penile prosthesis surgery at a teaching institution. Urology 2003; 62: 918.
834. Lubensky JD: Outpatient 3-piece inflatable penile prosthesis. J Urol 1991; 145: 1176.
835. Lux M, Reyes-Vallejo L, Morgentaler A et al: Outcomes and satisfaction rates for the redesigned 2-piece penile prosthesis. J Urol 2007; 177: 262.
836. Lynch MJ, Scott GM, Inglis JA et al: Reducing the loss of implants following penile prosthetic surgery. Br J Urol 1994; 73: 423.
837. Malloy TR, Wein AJ and Carpiniello VL: Reliability of AMS 700 inflatable penile prosthesis. Urology 1986; 28: 385.
838. Manning M, Martinez FJ, Alken P et al: Spontaneous tumescence after implantation of three-piece hydraulic penile prostheses: a short-term experience. Int J Impot Res 2003; 15: 152.
839. Mansi MK: Penile prosthesis: long-term follow up. Saudi Med J 1996; 17: 365.
840. McLaren RH and Barrett DM: Patient and partner satisfaction with the AMS 700 penile prosthesis. J Urol 1992; 147: 62.
841. Merrill DC: Clinical experience with the mentor inflatable penile prosthesis in 301 patients. J Urol 1988; 140: 1424.
842. Milbank AJ, Montague DK, Angermeier KW et al: Mechanical failure of the American Medical Systems Ultrex inflatable penile prosthesis: before and after 1993 structural modification. J Urol 2002; 167: 2502.
843. Minervini A, Ralph DJ and Pryor JP: Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. BJU Int 2006; 97: 129.
844. Miranda-Sousa A, Keating M, Moreira S et al: Concomitant ventral phalloplasty during penile implant surgery: a novel procedure that optimizes patient satisfaction and their perception of phallic length after penile implant surgery. J Sex Med 2007; 4: 1494.
845. Mirheydar H, Zhou T, Chang DC et al: Reoperation rates for penile prosthetic surgery. J Sex Med 2016; 13: 129.
846. Moncada I, Martinez-Salamanca JI, Jara J et al: Inflatable penile prosthesis implantation without corporeal dilation: a cavernous tissue sparing technique. J Urol 2010; 183: 1123.
847. Montorsi F, Rigatti P, Carmignani G et al: AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur Urol 2000; 37: 50.
848. Gittens P, Moskovic DJ, Avila D, Jr. et al: Favorable female sexual function is associated with patient satisfaction after inflatable penile prosthesis implantation. J Sex Med 2011; 8: 1996.
849. Moul JW and McLeod DG: Experience with the AMS 600 malleable penile prosthesis. J Urol 1986; 135: 929.
850. Mulhall JP, Ahmed A, Branch J et al: Serial assessment of efficacy and satisfaction profiles following penile prosthesis surgery. J Urol 2003; 169: 1429.
851. Natali A, Olianas R and Fisch M: Penile implantation in Europe: successes and complications with 253 implants in Italy and Germany. J Sex Med 2008; 5: 1503.
852. Negro CL, Paradiso M, Rocca A et al: Implantation of AMS 700 LGX penile prosthesis preserves penile length without the need for penile lengthening procedures. Asian J Androl 2016; 18: 114.
853. Nickas ME, Kessler R and Kabalin JN: Long-term experience with controlled expansion cylinders in the AMS 700CX inflatable penile prosthesis and comparison with earlier versions of the Scott inflatable penile prosthesis. Urology 1994; 44: 400.
854. Nukui F, Okamoto S, Nagata M et al: Complications and reimplantation of penile implants. Int J Urol 1997; 4: 52.
855. Ohl DA, Brock G, Ralph D et al: Prospective evaluation of patient satisfaction, and surgeon and patient trainer assessment of the Coloplast Titan one touch release three-piece inflatable penile prosthesis. J Sex Med 2012; 9: 2467.
856. Paranhos M, Andrade E, Antunes AA et al: Penile prosthesis implantation in an academic institution in Latin America. Int Braz J Urol 2010; 36: 591.
857. Pescatori E, Alei G, Antonini G et al: INSIST-ED: Italian Society of Andrology registry on penile prosthesis surgery. First data analysis. Arch Ital Urol Androl 2016; 88: 122.
858. Pozza D, Pozza M, Musy M et al: 500 penile prostheses implanted by a surgeon in Italy in the last 30 years. Arch Ital Urol Androl 2015; 87: 216. 859. Randrup ER: Clinical experience with 180 inflatable penile prostheses. South Med J 1995; 88: 47.
860. Randrup E, Wilson S, Mobley D et al: Clinical experience with Mentor Alpha I inflatable penile prosthesis. Report on 333 cases. Urology 1993; 42: 305.
861. Rogers E and Murphy DM: Use of the AMS inflatable penile prosthesis in the management of erectile impotence. Ir Med J 1997; 90: 105.
862. Salama N: Satisfaction with the malleable penile prosthesis among couples from the Middle East--is it different from that reported elsewhere? Int J Impot Res 2004; 16: 175.
863. Salem EA, Wilson SK, Neeb A et al: Mechanical reliability of AMS 700 CX improved by parylene coating. J Sex Med 2009; 6: 2615.
864. Saypol DC, Uhran CM and Stockman JC: Treatment of erectile failure with inflatable prostheses: three-year experience. N J Med 1987; 84: 191.
865. Scarzella GI: Reliability of the AMS inflatable prostheses in 444 consecutive cases. Arch Ital Urol Androl 1993; 65: 661.
866. Scarzella GI: Cylinder reliability of inflatable penile prosthesis. Experience with distensible and nondistensible cylinders in 325 patients. Urology 1988; 31: 486.
867. Serefoglu EC, Mandava SH, Gokce A et al: Long-term revision rate due to infection in hydrophilic-coated inflatable penile prostheses: 11-year follow-up. J Sex Med 2012; 9: 2182.
868. Sevinc C, Ozkaptan O, Balaban M et al: Outcome of penile prosthesis implantation: are malleable prostheses an appropriate treatment option in patients with erectile dysfunction caused by prior radical surgery? Asian J Androl 2016; 4: 477.
869. Simsek A, Kucuktopcu O, Ozgor F et al: Self and partner satisfaction rates after 3 part inflatable penile prosthesis implantation. Arch Ital Urol Androl 2014; 86: 219.
870. Song WD, Yuan YM, Cui WS et al: Penile prosthesis implantation in Chinese patients with severe erectile dysfunction: 10-year experience. Asian J Androl 2013; 15: 658.
871. Tefilli MV, Dubocq F, Rajpurkar A et al: Assessment of psychosexual adjustment after insertion of inflatable penile prosthesis. Urology 1998; 52: 1106.
872. Thomas AZ, Carrol R, Manecksha RP et al: Extended long term functional outcome of inflatable penile prosthesis in a single institution. Ir Med J 2011; 104: 53.
873. Vakalopoulos I, Kampantais S, Ioannidis S et al: High patient satisfaction after inflatable penile prostheses implantation correlates with female partner satisfaction. J Sex Med 2013; 10: 2774.
874. Vitarelli A, Divenuto L, Fortunato F et al: Long term patient satisfaction and quality of life with AMS700CX inflatable penile prosthesis. Arch Ital Urol Androl 2013; 85: 133.
875. Whalen RK and Merrill DC: Patient satisfaction with mentor inflatable penile prosthesis. Urology 1991; 37: 531.
876.Wilson SK and Delk JR, 2nd: Inflatable penile implant infection: predisposing factors and treatment suggestions. J Urol 1995; 153: 659.
877. Wilson SK, Carson CC, Cleves MA et al: Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol 1998; 159: 1537.
878. Wilson SK, Cleves MA and Delk JR 2nd: Comparison of mechanical reliability of original and enhanced Mentor Alpha I penile prosthesis. J Urol 1999; 162: 715.
879. Wilson SK, Delk JR, Salem EA et al: Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med 2007; 4: 1074.
880. Woodworth BE, Carson CC and Webster GD: Inflatable penile prosthesis: effect of device modification on functional longevity. Urology 1991; 38: 533.
881. Zabar KJ, Ahmadi A and Jalal AA: Penile prosthesis implantation for the treatment of erectile dysfunction. Bahrain Medical Bulletin 2009; 31: 2.
882. Zhu YC, Zhao JL, Wu YG et al: Clinical features and treatment options for Chinese patients with severe primary erectile dysfunction. Urology 2010; 76: 387.
883. Antonini G, Busetto GM, De Berardinis E et al: Penile prosthesis implant for erectile dysfunction: a new minimally invasive infrapubic surgical technique. Arch Ital Urol Androl 2015; 87: 322.
884. Menard J, Tremeaux JC, Faix A et al: Erectile function and sexual satisfaction before and after penile prosthesis implantation in radical prostatectomy patients: a comparison with patients with vasculogenic erectile dysfunction. J Sex Med 2011; 8: 3479.
885. Kim YD, Yang SO, Lee JK et al: Usefulness of a malleable penile prosthesis in patients with a spinal cord injury. Int J Urol 2008; 15: 919.
886. Kramer AC and Schweber A: Patient expectations prior to Coloplast Titan penile prosthesis implant predicts postoperative satisfaction. J Sex Med 2010; 7: 2261.
887. Nehra A, Carson CC 3rd, Chapin AK et al: Long-term infection outcomes of 3-piece antibiotic impregnated penile prostheses used in replacement implant surgery. J Urol 2012; 188: 899.
888. Mulcahy JJ and Carson CC 3rd: Long-term infection rates in diabetic patients implanted with antibiotic-impregnated versus nonimpregnated inflatable penile prostheses: 7-year outcomes. Eur Urol 2011; 60: 167.
889. Christodoulidou M and Pearce I: Infection of penile prostheses in patients with diabetes mellitus. Surg Infect (Larchmt) 2016; 17: 2.
890. Deveci S, Martin D, Parker M et al: Penile length alterations following penile prosthesis surgery. Eur Urol 2007; 51: 1128.
891. Wang R, Howard GE, Hoang A et al: Prospective and long-term evaluation of erect penile length obtained with inflatable penile prosthesis to that induced by intracavernosal injection. Asian J Androl 2009; 11: 411.
892. Levine LA and Rybak J: Traction therapy for men with shortened penis prior to penile prosthesis implantation: a pilot study. J Sex Med 2011; 8: 2112.
893. Canguven O, Talib RA, Campbell J et al: Is the daily use of vacuum erection device for a month before penile prosthesis implantation beneficial? A randomized controlled trial. Andrology 2017; 5: 103.
894. Pahlajani G, Raina R, Jones S et al: Vacuum erection devices revisited: its emerging role in the treatment of erectile dysfunction and early penile rehabilitation following prostate cancer therapy. J Sex Med 2012; 9: 1182.
895. Tsambarlis PN, Chaus F and Levine LA: Successful placement of penile prostheses in men with severe corporal fibrosis following vacuum therapy protocol. J Sex Med 2017; 14: 44.
896. Henry GD, Kansal NS, Callaway M et al: Centers of excellence concept and penile prostheses: an outcome analysis. J Urol 2009; 181: 1264.
897. Hakky TS, Suber J, Henry G et al: Penile enhancement procedures with simultaneous penile prosthesis placement. Adv Urol 2012; 2012: doi:10.1155/2012/314612.
898. Chew KK and Stuckey BG: Use of transurethral alprostadil (MUSE) (prostaglandin E1) for glans tumescence in a patient with penile prosthesis. Int J Impot Res 2000; 12: 195.
899. Benevides MD and Carson CC: Intraurethral application of alprostadil in patients with failed inflatable penile prosthesis. J Urol 2000; 163: 785.
900. Mulhall JP, Jahoda A, Aviv N et al: The impact of sildenafil citrate on sexual satisfaction profiles in men with a penile prosthesis in situ. BJU Int 2004; 93: 97.
901. Pryor MB, Carrion R, Wang R et al: Patient satisfaction and penile morphology changes with postoperative penile rehabilitation 2 years after Coloplast Titan prosthesis. Asian J Androl 2016; 18: 754.
902. Anafarta K, Aydos K and Yaman O: Is deep dorsal vein arterialization an alternative surgical approach to treat venogenic impotence? Urol Int 1997; 59: 109.
903. Austoni E, Colombo F, Mantovani F et al: Venous surgery in erectile dysfunction: therapeutic strategy and results. Urol Int 1992; 49: 63.
904. Balko A, Malhotra CM and Wincze JP: Deep-penile-vein arterialization for arterial and venous impotence. Arch Surg 1986; 121: 774.
905. Cookson MS, Phillips DL, Huff ME et al: Analysis of microsurgical penile revascularization results by etiology of impotence. J Urol 1993; 149: 1308.
906. Crespo E, Bove D, Farrell G et al: Revascularization of the cavernous body in vasculogenic sexual male impotence with a new microsurgical technique. Cardiovasc Res Cent Bull 1983; 22: 29.
907. DePalma RG, Olding M, Yu GW et al: Vascular interventions for impotence: lessons learned. J Vasc Surg 1995; 21: 576.
908. Frankovicova M and Thoma A: Microvascular treatment of impotence. Plast Reconstr Surg 1993; 91: 99.
909. Grasso M, Lania C, Castelli M et al: Deep dorsal vein arterialization in vasculogenic impotence: our experience. Arch Ital Urol Nefrol Androl 1992; 64: 309.
910. Hatzinger M, Seemann O, Grenacher L et al: Laparoscopy-assisted penile revascularization: a new method. J Endourol 1997; 11: 269.
911. Janssen T, Sarramon JP, Rischmann P et al: Microsurgical arterio-arterial and arterio-venous penile revascularization in patients with pure arteriogenic impotence. Br J Urol 1994; 73: 561.
912. Jarow JP and DeFranzo AJ: Long-term results of arterial bypass surgery for impotence secondary to segmental vascular disease. J Urol 1996; 156: 982.
913. Kaufman JM, Kaufman JL and Fitch WP 3rd: Deep dorsal vein arterialization in arteriogenic impotence: use of the dorsal artery as a neoarterial source. Int J Impot Res 1995; 7: 157.
914. Kawanishi Y, Kimura K, Nakanishi R et al: Penile revascularization surgery for arteriogenic erectile dysfunction: the long-term efficacy rate calculated by survival analysis. BJU Int 2004; 94: 361.
915. Kayigil O, Agras K and Okulu E: Is deep dorsal vein arterialization effective in elderly patients? Int Urol Nephrol 2008; 40: 125.
916. Kayigil O, Ahmed SI and Metin A: Deep dorsal vein arterialization in pure cavernoocclusive dysfunction. Eur Urol 2000; 37: 345.
917. Kayigil O, Okulu E, Aldemir M et al: Penile revascularization in vasculogenic erectile dysfunction (ED): long-term follow-up. BJU Int 2012; 109: 109.
918. Knoll LD: Penile dorsal vein arterialization in managing venogenic impotence. Tech Urol 1995; 1: 157.
919. Lizza EF and Zorgniotti AW: Experience with the long-term effect of microsurgical penile revascularization. Int J Impot Res 1994; 6: 145.
920. Lobelenz M, Junemann KP, Kohrmann KU et al: Penile revascularization in nonresponders to intracavernous injections using a modified microsurgical technique. Eur Urol 1992; 21: 120.
921. Lukkarinen O, Tonttila P, Hellstrom P et al: Non-prosthetic surgery in the treatment of erectile dysfunction. A retrospective study of 45 impotent patients in the University of Oulu. Scand J Urol Nephrol 1998; 32: 42.
922. Manning M, Junemann KP, Scheepe JR et al: Long-term followup and selection criteria for penile revascularization in erectile failure. J Urol 1998; 160: 1680.
923. Melman A and Riccardi R, Jr.: The success of microsurgical penile revascularization in treating arteriogenic impotence. Int J Impot Res 1993; 5: 47.
924. Michal V, Kramar R, Pospichal J et al: Arterial epigastricocavernous anastomosis for the treatment of sexual impotence. World J Surg 1977; 1: 515.
925. Munarriz R, Uberoi J, Fantini G et al: Microvascular arterial bypass surgery: long-term outcomes using validated instruments. J Urol 2009; 182: 643.
926. Sarramon JP, Bertrand N, Malavaud B et al: Microrevascularisation of the penis in vascular impotence. Int J Impot Res 1997; 9: 127.
927. Sarramon JP, Malavaud B, Braud F et al: Evaluation of male sexual function by the International Index of Erectile Function after deep dorsal vein arterialization of the penis. J Urol 2001; 166: 576.
928. Schramek P, Engelmann U and Kaufmann F: Microsurgical arteriovenous revascularization in the treatment of vasculogenic impotence. J Urol 1992; 147: 1028.
929. Sohn M, Sikora R, Bohndorf K et al: Selective microsurgery in arteriogenic erectile failure. World J Urol 1990; 8: 104.
930. Vardi Y, Gruenwald I, Gedalia U et al: Evaluation of penile revascularization for erectile dysfunction: a 10-year follow-up. Int J Impot Res 2004; 16: 181.
931. Virag R and Bennett AH: Arterial and venous surgery for vasculogenic impotence: a combined French and American experience. Arch Ital Urol Nefrol Androl 1991; 63: 95.
932. Wespes E, Corbusier A, Delcour C et al: Deep dorsal vein arterialisation in vascular impotence. Br J Urol 1989; 64: 535.
933. Wespes E, Wildschutz T, Roumeguere T et al: The place of surgery for vascular impotence in the third millennium. J Urol 2003; 170: 1284.
934. Zumbe J, Drawz G, Wiedemann A et al: Indications for penile revascularization and long-term results. Andrologia 1999; 31 Suppl 1: 83.
935. Munarriz R: Penile microvascular arterial bypass surgery: indications, outcomes, and complications. ScientificWorldJournal 2010; 10: 1556.
936. Dabaja AA, Teloken P and Mulhall JP: A critical analysis of candidacy for penile revascularization. J Sex Med 2014; 11: 2327.
937. Afsar H, Metin A, Sozduyar N et al: Erectile dysfunction due to venous incompetence treated by dorsal vein ligation. Int Urol Nephrol 1992; 24: 65.
938. Anafarta K, Beduk Y, Aydos K et al: Treatment of impotence due to venous leakage by resection of the deep dorsal vein of the penis. Urol Int 1992; 48: 332.
939. Bar-Moshe O and Vandendris M: Surgical approach of venous leakage. Urol Int 1992; 49: 19.
940. Berardinucci D, Morales A, Heaton JP et al: Surgical treatment of penile veno-occlusive dysfunction: is it justified? Urology 1996; 47: 88.
941. Cakan M, Yalcinkaya F, Demirel F et al: Is dorsale penile vein ligation (DPVL) still a treatment option in veno-occlusive dysfunction? Int Urol Nephrol 2004; 36: 381.
942. Cayan S: Primary penile venous leakage surgery with crural ligation in men with erectile dysfunction. J Urol 2008; 180: 1056.
943. Chen SC, Hsieh CH, Hsu GL et al: The progression of the penile vein: could it be recurrent? J Androl 2005; 26: 53.
944. Claes H and Baert L: Pelvic floor exercise versus surgery in the treatment of impotence. Br J Urol 1993; 71: 52.
945. Claro Jde A, de Lima ML and Netto Junior N: Surgical treatment of veno-occlusive dysfunction: evaluation of short-term and long-term results. Rev Paul Med 1992; 110: 280.
946. Flores S, Tal R, O'Brien K et al: Outcomes of crural ligation surgery for isolated crural venous leak. J Sex Med 2011; 8: 3495.
947. Fowlis GA, Sidhu PS, Jager HR et al: Preliminary report--combined surgical and radiological penile vein occlusion for the management of impotence caused by venous-sinusoidal incompetence. Br J Urol 1994; 74: 492.
948. Freedman AL, Costa Neto F, Mehringer CM et al: Long-term results of penile vein ligation for impotence from venous leakage. J Urol 1993; 149: 1301.
949. Gilbert P, Sparwasser C, Beckert R et al: Venous surgery in erectile dysfunction. The role of dorsal-penile-vein ligation and spongiosolysis for impotence. Urol Int 1992; 49: 40.
950. Hassan AA, Hassouna MM and Elhilali MM: Long-term results of penile venous ligation for corporeal venous occlusive dysfunction. Can J Surg 1995; 38: 537.
951. Hirsch M, Lubetsky R, Goldman H et al: Dorsal vein sclerosis as a predictor of outcome in penile venous ligation surgery. J Urol 1993; 150: 1810.
952. Hsu GL, Chen HS, Hsieh CH et al: Clinical experience of a refined penile venous stripping surgery procedure for patients with erectile dysfunction: is it a viable option? J Androl 2010; 31: 271.
953. Hwang TI and Yang CR: Penile vein ligation for venogenic impotence. Eur Urol 1994; 26: 46.
954. Katzenwadel A, Popken G and Wetterauer U: Penile venous surgery for cavernosal venous leakage: long-term results and retrospective studies. Urol Int 1993; 50: 71.
955. Kerfoot WW, Carson CC, Donaldson JT et al: Investigation of vascular changes following penile vein ligation. J Urol 1994; 152: 884.
956. Kim ED and McVary KT: Long-term results with penile vein ligation for venogenic impotence. J Urol 1995; 153: 655.
957. Knoll LD, Furlow WL and Benson RC: Penile venous ligation surgery for the management of cavernosal venous leakage. Urol Int 1992; 49: 33.
958. Kropman RF, Lycklama Nijeholt AAAB, Odink HF et al: Treatment of impotence caused by veno-occlusive dysfunction with detachable balloons and coils in combination with resection of the deep dorsal vein: comparison with resection of the deep dorsal vein only. World J Urol 1992; 10: 226.
959. Lewis RW: Results of surgery for veno-occlusive disease. J Sex Marital Ther 1991; 17: 129.
960. Lunglmayr G, Nachtigall M and Gindl K: Long-term results of deep dorsal penile vein transsection in venous impotence. Eur Urol 1988; 15: 209.
961. McLoughlin J, Asopa R and Williams G: Surgical treatment of venous leakage: medium-term follow-up. Eur Urol 1993; 23: 352.
962. Miwa Y, Shioyama R, Itou Y et al: Pelvic venoablation with ethanol for the treatment of erectile dysfunction due to veno-occlusive dysfunction. Urology 2001; 58: 76.
963. Montague DK, Angermeier KW, Lakin MM et al: Penile venous ligation in 18 patients with 1 to 3 years of followup. J Urol 1993; 149: 306.
964. Motiwala HG, Patel DD, Joshi SP et al: Experience with penile venous surgery. Urol Int 1993; 51: 9.
965. Netto Jr NR, Cara A, Reinato JAS et al: Cavernosometry: corroboratory method to surgical treatment of impotence due to venous leakage. Urology 1990; 35: 35.
966. Ng FC, Ruan XQ, Wong HT et al: Venous ligation for cavernous leak impotence--a report on 30 cases. Ann Acad Med Singapore 1995; 24: 716.
967. Nikoobakht M, Saraji A and Meysamie A: Preoperative corporal biopsy as a predictor of postoperative results in venoocclusive erectile dysfunction. Urol J 2005; 2: 160.
968. Parrott LH, Sholes AH, Rice JC et al: Penile vein dissection: a study of its long-term efficacy in impotence. World J Urol 1989; 7: 169.
969. Petrou S and Lewis RW: Management of corporal veno-occlusive dysfunction. Urol Int 1992; 49: 48.
970. Popken G, Katzenwadel A and Wetterauer U: Long-term results of dorsal penile vein ligation for symptomatic treatment of erectile dysfunction. Andrologia 1999; 31 Suppl 1: 77.
971. Rossman B, Mieza M and Melman A: Penile vein ligation for corporeal incompetence: an evaluation of short-term and long-term results. J Urol 1990; 144: 679.
972. Sasso F, Gulino G, Di Pinto A et al: Should venous surgery be still proposed or neglected? Int J Impot Res 1996; 8: 25.
973. Sasso F, Gulino G, Weir J et al: Patient selection criteria in the surgical treatment of veno-occlusive dysfunction. J Urol 1999; 161: 1145.
974. Schultheiss D, Truss MC, Becker AJ et al: Long-term results following dorsal penile vein ligation in 126 patients with veno-occlusive dysfunction. Int J Impot Res 1997; 9: 205.
975. Stief CG, Djamilian M, Truss MC et al: Prognostic factors for the postoperative outcome of penile venous surgery for venogenic erectile dysfunction. J Urol 1994; 151: 880.
976. Da Ros CT, Teloken C, Antonini CC et al: Long-term results of penile vein ligation for erectile dysfunction due to cavernovenous disease. Tech Urol 2000; 6: 172.
977. Torok A, Szekely J, Mark B et al: Surgical treatment of impotence due to venous outflow. Int Urol Nephrol 1989; 21: 485.
978. Treiber U and Gilbert P: Venous surgery in erectile dysfunction: a critical report on 116 patients. Urology 1989; 34: 22.
979. Tsai TC, Hsu GL, Chen SC et al: Analysis of the results of reconstructive surgery for vasculogenic impotence. Taiwan Yi Xue Hui Za Zhi 1988; 87: 182.
980. Vale JA, Feneley MR, Lees WR et al: Venous leak surgery: long-term follow-up of patients undergoing excision and ligation of the deep dorsal vein of the penis. Br J Urol 1995; 76: 192.
981. Wagenknecht LV: New treatment of increased venous drainage in organic impotence: ligation of internal iliac veins. Eur Urol 1989; 16: 172.
982. Weidner W, Weiske WH, Rudnick J et al: Venous surgery in veno-occlusive dysfunction: long-time results after deep dorsal vein resection. Urol Int 1992; 49: 24.
983. Wespes E and Schulman CC: Venous leakage: surgical treatment of a curable cause of impotence. J Urol 1985; 133: 796.
984. Wespes E, Moreira de Goes P, Sattar AA et al: Objective criteria in the long-term evaluation of penile venous surgery. J Urol 1994; 152: 888.
985. Wespes E, Delcour C, Preserowitz L et al: Impotence due to corporeal veno-occlusive dysfunction: long-term follow-up of venous surgery. Eur Urol 1992; 21: 115.
986. Williams G, Mulcahy MJ, Hartnell G et al: Diagnosis and treatment of venous leakage: a curable cause of impotence. Br J Urol 1988; 61: 151.
987. Yu GW, Schwab FJ, Melograna FS et al: Preoperative and postoperative dynamic cavernosography and cavernosometry: objective assessment of venous ligation for impotence. J Urol 1992; 147: 618.
988. Vardi Y, Appel B, Kilchevsky A et al: Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol 2012; 187: 1769.
989. Srini VS, Reddy RK, Shultz T et al: Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population. Can J Urol 2015; 22: 7614.
990. Olsen AB, Persiani M, Boie S et al: Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebo-controlled study. Scand J Urol 2015; 49: 329.
991. Kalyvianakis D and Hatzichristou D: Low-intensity shockwave therapy improves hemodynamic parameters in patients with vasculogenic erectile dysfunction: a triplex ultrasonography-based sham-controlled trial. J Sex Med 2017; 14: 891.
992. Kitrey ND, Gruenwald I, Appel B et al: Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, sham controlled study. J Urol 2016; 195: 1550.
993. Yee CH, Chan ES, Hou SS et al: Extracorporeal shockwave therapy in the treatment of erectile dysfunction: a prospective, randomized, double-blinded, placebo controlled study. Int J Urol 2014; 21: 1041.
994. Fojecki GL, Tiessen S and Osther PJ: Effect of low-energy linear shockwave therapy on erectile dysfunction-a double-blinded, sham-controlled, randomized clinical trial. J Sex Med 2017; 14: 106.
995 Clavijo RI, Kohn TP, Kohn JR et al: Effects of low-intensity extracorporeal shockwave therapy on erectile dysfunction: a systematic review and meta-analysis. J Sex Med 2017; 14: 27.
996.Angulo JC, Arance I, de Las Heras MM et al: Efficacy of low-intensity shock wave therapy for erectile dysfunction: a systematic review and meta-analysis. Actas Urol Esp 2017; 41: 479.
997. Lu Z, Lin G, Reed-Maldonado A et al: Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. Eur Urol 2017; 71: 223.
998. Zou ZJ, Tang LY, Liu ZH et al: Short-term efficacy and safety of low-intensity extracorporeal shock wave therapy in erectile dysfunction: a systematic review and meta-analysis. Int Braz J Urol 2017; 43: 805.
999. Bahk JY, Jung JH, Han H et al: Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant 2010; 8: 150.
1000. Garber MG and Carlos, ND: Intracavernous administration of adipose stem cells: a new technique of treating erectile dysfunction in diabetic patient, preliminary report of 6 cases. MOJ Cell Sci Rep 2015; 1: 0001
1001. Yiou R, Hamidou L, Birebent B et al: Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. Eur Urol 2016; 69: 988.
1002. Haahr MK, Jensen CH, Toyserkani NM et al: Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. EBioMedicine 2016; 5: 204.
1003. Levy JA, Marchand M, Iorio L et al: Determining the feasibility of managing erectile dysfunction in humans with placental-derived stem cells. J Am Osteopath Assoc 2016; 116: e1.
1004. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
1005. https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/index.html
1006. Carter HB, Albertsen PC, Barry MJ, et al. Early Detection of Prostate Cancer: AUA Guideline.J Urol 2013; 2:419-426.
1007. Mulhall JP, Trost LW, Brannigan RE et al: Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol 2018; doi 10.1016/j.juro.2018.03.115.
